1

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH

+ + + + +

ADVISORY BOARD ON RADIATION AND WORKER HEALTH

+ + + + +

WORK GROUP ON WELDON SPRING

+ + + + +

MONDAY MAY 9, 2011

+ + + + +

The Work Group convened in the Frankfurt Room of the Cincinnati Airport Marriott, 2395 Progress Drive, Hebron, Kentucky, at 9:00 a.m., Michael H. Gibson, Chairman, presiding.

PRESENT:

MICHAEL H. GIBSON, Chairman RICHARD A. LEMEN, Member ROBERT W. PRESLEY, Member*

ALSO PRESENT:

TED KATZ, Designated Federal Official RON BUCHANAN, SC&A MEL CHEW, ORAU Team* JOE FITZGERALD, SC&A MONICA HARRISON-MAPLES, ORAU Team* KAREN JOHNSON* MARY JOHNSON* JENNY LIN, HHS JOHN MAURO, SC&A* ROBERT MORRIS, ORAU Team* GENE POTTER, ORAU Team* BRYCE RICH, ORAU Team* MARK ROLFES, DCAS MATTHEW SMITH, ORAU* BILLY SMITH, ORAU Team* JOHN STIVER, SC&A* DAVE SUNDIN, DCAS TINA TRIPLETT*

*Participating via telephone

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

www.nealrgross.com

2

3

C-O-N-T-E-N-T-S

Wel	come and Introductions4
1.	Brief Review of Weldon Spring Site and SEC petition - SC&A
2.	Progress report on SC&A's action items - SC&A 11
3.	Progress report on NIOSH's action items - NIOSH 119
4.	Discussion of SEC issues - NIOSH and SC&A 202
5.	Discussion/assignment of action items to be completed before AB meeting the end of May 219

4

1	P-R-O-C-E-E-D-I-N-G-S
2	9:01 a.m.
3	MR. KATZ: Good morning everybody
4	on the line. This is the Advisory Board on
5	Radiation Health. Welcome to spring Work
6	Group. We're just getting started, getting
7	ready for roll call here while the Chair looks
8	for a chair. Let me just check with Mr.
9	Presley, are you on the line, Bob?
10	MEMBER PRESLEY: Yes.
11	MR. KATZ: Great. Good morning.
12	How are you?
13	MEMBER PRESLEY: Good morning.
14	MR. KATZ: So let's start with
15	roll call. Since we're speaking about a
16	specific site please speak to conflict of
17	interest. Beginning with Board Members, the
18	Chair in the room.
19	CHAIRMAN GIBSON: Mike Gibson,
20	Chair of the Work Group. No conflict.
21	MEMBER LEMEN: Richard Lemen,

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

5

1	Board Member, no conflict other than being
2	raised in Missouri.
3	MEMBER PRESLEY: Bob Presley,
4	Board Member, no conflict.
5	MR. KATZ: Are there any other
6	Board Members on the line? Okay. NIOSH ORAU
7	team in the room.
8	MR. SUNDIN: Dave Sundin, no
9	conflict.
10	MR. ROLFES: Mark Rolfes, NIOSH
11	health physicist, no conflict of interest.
12	MR. KATZ: NIOSH ORAU team on the
13	line.
14	MS. HARRISON-MAPLES: This is
15	Monica Harrison-Maples, ORAU team, no
16	conflict.
17	DR. CHEW: Mel Chew, ORAU team, no
18	conflict.
19	MR. MORRIS: Robert Morris, ORAU
20	team, no conflict.
21	MR. RICH: Bryce Rich, ORAU team,

NEAL R. GROSS

б

1	no conflict.
2	MR. B. SMITH: Billy Smith, ORAU
3	team, no conflict.
4	MR. M. SMITH: Matthew Smith,
5	ORAU, no conflict.
6	MR. KATZ: Welcome all of you.
7	SC&A team in the room.
8	MR. FITZGERALD: Joe Fitzgerald,
9	SC&A, no conflict.
10	DR. BUCHANAN: Ron Buchanan, SC&A,
11	no conflict.
12	MR. KATZ: And SC&A team on the
13	line.
14	DR. MAURO: John Mauro, SC&A, no
15	conflict.
16	MR. STIVER: John Stiver, SC&A, no
17	conflict.
18	MR. KATZ: Welcome to both of you
19	on the line. There are no members of the
20	public in the room. Any members of the public
21	on the line?

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

7

1	MS. K. JOHNSON: This is Karen
2	Johnson and my mother Mary Johnson.
3	MS. TRIPLETT: And Tina Triplett.
4	MR. KATZ: Welcome Ms. Johnson and
5	Ms. Triplett. And HHS or other federal
6	officials or contractors of the feds in the
7	room?
8	MS. LIN: Jenny Lin, HHS.
9	MR. KATZ: And on the line?
10	(No response.)
11	MR. KATZ: Okay, that does it for
12	roll call. Let me just remind folks on the
13	line to mute your phones except when you're
14	speaking to the group, *6 if you don't have a
15	mute button and then press *6 again to take
16	yourself off mute. And Mike, the agenda is
17	yours.
18	CHAIRMAN GIBSON: Okay. I'd like
19	to thank everyone for being here. It's been
20	awhile since our last meeting. We've had -
21	the program's been pretty busy so we've had a

NEAL R. GROSS

(202) 234-4433

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

8

1	little trouble getting some things
2	accomplished between NIOSH and SC&A but I
3	think we have enough put together today to
4	have a meeting. I thank SC&A for putting out
5	a draft agenda that we're going to try to
6	stick to. I have some things that have been
7	discussed and possibly resolved between SC&A
8	and Weldon Spring so we'll just, we'll start
9	at the top of the agenda and go with that. So
10	if, Ron, if you want to start out.
11	DR. BUCHANAN: Okay.
12	MR. KATZ: Let me just note for
13	the folks on the phone the agenda is on the
14	internet. It's on the NIOSH website or it
15	should be, under the board section. Go ahead,
16	Ron.
17	DR. BUCHANAN: Okay. This is Ron
18	Buchanan of SC&A and this is our third meeting
19	on Weldon Spring Work Group, the SEC. And so
20	I know that we've - it was January 25th since
21	we had our last meeting and so I think it'd be

NEAL R. GROSS

(202) 234-4433

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

9

1	beneficial if I just do a very brief recap of
2	Weldon Spring and where we're at on the Site
3	Profile and the SEC issues and then we'll
4	discuss some in detail. I'll discuss SC&A's
5	action items first since we have a shorter
6	list and then turn it over to NIOSH to discuss
7	their action items. Then we'll have a mutual
8	discussion of the issues and where we need to
9	go from there.

10 So just a brief recap. Weldon Spring of course was an Army ammunition site 11 12 from the '40s through to '53 or so and then in '54 13 to '57 they constructed the uranium processing plant there. '57 to '66 it was in 14 15 operation and these dates have something to do 16 with SEC issues, it's the reason I'm going There in '57 to '66 they received 17 over them. uranium yellowcake ore which they processed 18 into mostly uranium metals. They did receive 19 some recycled uranium starting in the early 20 They received some enriched uranium in 21 '60s.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

10

1	'63 to '67 and some recycled uranium right
2	along in that time period too.
3	Then in December 31st, 1966 was
4	the official close-down date of the plant.
5	The 1967 to 1969 was a period that they were
6	going to generate Agent Orange at the
7	facility. There were some renovations done
8	but that never actually took place. It laid
9	in monitoring and maintenance from '70 to '85.
10	And in '85 to 2001 it was a decommissioning
11	period and it was all the plant and the quarry
12	and the pits were taken and put into an
13	engineering disposal pile which is, if you've
14	ever been there, it was finished in about
15	2002. It's a big white pyramid-looking rock
16	stone structure with all the material inside
17	encased in some cement, slurry and that sort
18	of thing. So that's - and of course it's
19	under monitoring now and there's a visitor
20	station there that you can get information
21	from.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

11

1	And so SC&A went there, we
2	interviewed some of the workers when we
3	received the Site Profile. And then the SEC
4	was evaluated by NIOSH after it had been filed
5	and they had done a Site Profile in June of
6	2005. SC&A issued their review of the Site
7	Profile in March of 2009 and we started with
8	that about a year before that. In April 2010
9	NIOSH issued their ER report for SEC 143
10	covering the period 1957 through 1967. We had
11	our first Work Group meeting in October of
12	2010 here in Cincinnati. I've outlined some
13	of the issues. In December of 2010 SC&A
14	issued their review of the ER report. In
15	January 25th of 2011 we had our second Work
16	Group meeting here and then we were scheduled
17	for one in March of 2011 and that was
18	postponed until today for our third Work Group
19	meeting. So that brings us a little up to
20	date of where we're at on the site. Any
21	comments or corrections to that?

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

12

1 MR. KATZ: Thank you, that is 2 helpful.

3 that's DR. BUCHANAN: Okay. So 4 the item one on the agenda. And so we want to 5 move to item two which is our progress report on SC&A's action item. 6 We just have four 7 action items from the January meeting and I should probably say that there was nine SEC 8 issues and 28 Site Profile issues. I did find 9 10 a lot of Site Profile issues were covered in The nine SEC issues were the data 11 SEC issues. 12 completeness, daily weighted and accuracy 13 for air exposure and we'll have a average 14 that little bit session on in a and then 15 coworker data. Number two is egress 16 monitoring. Number three was the data for 17 1967. Number four radon and thoron. was 18 Number five was recycled uranium. Number six 19 was neutrons. Number seven was quarries and 20 pits. Number eight accidents was and 21 incidents, and number nine was the geometry

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

13

1 and dosimetry.

And so of these nine SEC issues we 2 3 had four action items from the last group and one was the daily weighted average on air 4 This is where you use 5 concentration. the in the environmental - excuse 6 material me, 7 NIOSH's Evaluation Report on pages 39 through 45. They list the available data for air 8 sampling. And now the reason that we kind of 9 10 held off on this issue was Fernald had the 11 same issue. We didn't want to spend time doing it both at Weldon Spring and Fernald 12 13 since they're similar issues and Weldon Spring received their material from - most of their 14 material from Fernald. And so there was a 15 16 group that was working on the DWE for Fernald 17 and several papers went back and forth between Fernald and - I mean, excuse me, between NIOSH 18 and SC&A on Fernald. And so what we wanted to 19 20 do that ironed was to qet out and then extrapolate it to Weldon Spring. 21 And so we

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

14

1	have John Stiver on the phone. He's the one
2	that was handling this for SC&A and we'll put
3	him on in a minute. And so he has some
4	handouts that I'll hand out from the ER
5	report. John, are you there?
6	MR. STIVER: Yes, I am.
7	DR. BUCHANAN: Okay. Now, we
8	cannot hand out those slides but you can talk
9	through them because they haven't been
10	cleared, but I do have copies of the ER pages
11	that you wanted me to make. And so you want
12	to give a brief rundown of why this is an
13	issue and where we're going with it?
14	MR. KATZ: Ron, I mean you can
15	hand out here.
16	DR. BUCHANAN: I have the - the
17	data from the ER report. Yes.
18	MR. KATZ: Okay.
19	MR. STIVER: Yes, they're just
20	five pages from the Evaluation Report, a look
21	at the site-specific data. I thought it would

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

15

1	be handy for everybody to look at.
2	MR. FITZGERALD: What we were
3	sensitive of was the slides for obvious
4	reasons.
5	MR. KATZ: Oh, I see. Okay.
6	DR. BUCHANAN: PowerPoint
7	presentation. Okay, John could you give us a
8	brief -
9	MR. STIVER: Okay. I had just put
10	together some slides but it's really not
11	critical that everybody have them. We're
12	going to be talking in broad brush strokes for
13	the most part. However, I thought it would be
14	helpful for everybody to have the site-
15	specific data when we get to that point. And
16	what I wanted to do today is really kind of do
17	an overview and look at, you know, the DWE
18	concept and what it entails, what the
19	advantages and limitations are, look at some
20	of the historical milestones that led up to
21	this review and then take a look at the

NEAL R. GROSS

16

1 highlights from the Adam Davis and Dan Strom Health Physics Journal article in 2008 which 2 3 is really a seminal article that provides the fundamental underpinnings for the new NIOSH 4 I'll take a look at some of the 5 methodology. highlights of the NIOSH methodologies and then 6 7 finally get into the Weldon Spring sitespecific data and see if there are any issues 8 that may arise in applying those methods to 9 10 that particular data set.

11 Let's ahead and get started qo 12 here about the daily weighted exposure 13 concept. And this was a concept that was introduced by the Atomic Energy Commission's 14 Health and Safety Laboratory way back in the 15 16 1940s. And what they intended to do is really estimate of the average worker 17 provide an exposure by job type that would then be used 18 radioactive dust levels 19 to assess and to 20 better control those levels in a plant. And really 21 it's pretty amazing because that

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

17

1 methodology that was devised back in the '40s 2 was basically unchanged all the way through 3 into the late 1960s, especially at least at 4 Fernald when they finally introduced in vivo 5 accounting methods.

And so you have about a 20- and 6 7 25-year period where the methodologies did not change, a pretty good understanding of how it 8 was done and in many cases the raw data are 9 10 available for review. And this method is 11 based on the - basically a gross alpha air activity concentration measured on a filter 12 13 that was then counted in a zinc sulfide 14 detector. And it's applicable to workplace alpha emitters whether it be uranium, RU, 15 16 thorium and/or their progeny.

Take a little look at this here. 17 The time-weighted alpha air concentration in 18 individual is 19 the sample really the 20 fundamental unit of the DWE. They're job- and facility-specific. typically 21 There were

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

18

1	several tasks that were performed for any
2	given job. Again, I'm using Fernald as my
3	basis here. In that data set we had anywhere
4	from three to more than 20 tasks per job. And
5	the reports reported three values, a high
б	value, the low value and the average alpha air
7	concentration in units of dpm per cubic meter
8	of air. And this was reported for each task
9	associated with the job. The time to complete
10	the task was reported and also the sample type
11	which would be either a breathing zone sample
12	which would be like a lapel-type monitor that
13	an individual worker would wear during a task
14	and also fixed general air samples were placed
15	at various locations throughout the facility.
16	I had an example here which I had
17	shown at Fernald. It's actually the same
18	example that Bob Morris has in his - in the
19	NIOSH White Paper. And basically it's just a
20	table that shows, you know, it lays out how
21	the DWE reports were formatted. You have an

NEAL R. GROSS

(202) 234-4433

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

19

1	identification, a breathing zone, general air,
2	time per shift, give you the number of
3	samples, the high, the low, the average and
4	then how this would - the DWE would work. For
5	each of those tasks it would take the time to
6	create or to perform that particular task
7	multiplied by the average concentration. So
8	you'd have a time by average value which is
9	then summed up for all the different tasks and
10	then divided by the total amount of time per
11	day. So what you have then is a weighting by
12	- a time weighting for each given task.
13	I have an example here, we don't
14	really need to go through that particular
15	example. But in summary what you have, the
16	DWE represents a task-weighted average air
17	concentration for any given alpha emitter for
18	specific days in which the samples were
19	collected and for the monitored workers. And
20	the time-weighting is really the salient
21	feature of this methodology. It really kind

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

20

1 of gives a better idea of what workers were 2 actually exposed to. It's really the link 3 the air concentration at between а qiven potential 4 location time to the worker 5 exposure.

And in actuality what you have is 6 7 a distribution of DWEs because these processes were going on continuously for a number of 8 Not so much with thorium where you had 9 vears. 10 more of short-term campaigns that would last anywhere from a couple of months up to maybe a 11 year or so. But for uranium that was going on 12 13 all the time. And you have a few little 14 snapshots in time where these studies were And so you might, you know, you have an 15 done. 16 idea of what a particular worker was exposed to on a particular day for the time that the 17 sample was done, but you don't really know, 18 you know, how about all the workers for a 19 20 given period of time. So you really have a distribution 21 of these. And probably the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

21

1 biggest drawback to DWE was that there's no 2 uncertainty estimates were provided. And it 3 really wasn't intended to dose use as а estimate, it was really to control workplace 4 5 dust levels and potential exposures. So you 6 have spatial and temporal variation in air 7 concentration that were experienced by a given worker. 8

And now what I'd like to do is 9 10 kind of recap the history of this DWE issue for Fernald and Weldon Spring. Basically it's 11 a global issue and this methodology is really 12 13 applicable to any facility that used this 14 approach for assessing or estimating intakes. And my experience with this goes back to when 15 16 I first started with SC&A in February of 2009 their 17 and that's when NIOSH issued White Paper, revision 2 of the White Paper which we 18 Morris 2009. 19 called Bob Morris was the 20 author.

In July of 2009 SC&A issued our

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

21

22

1	White Paper that was in response to a Board
2	request that we do a review and we came up
3	with 20 findings in that paper. 19 October as
4	we know was the first Weldon Spring meeting
5	when the issue of DWE came up. In November
б	2010 NIOSH issued revision 3 of the White
7	Paper concerning DWEs but our review of that,
8	we came out a little too late and our review
9	of that methodology was based on revision 2.
10	We then issued another revision to our White
11	Paper which looked at Rev 3. And again, as
12	you know the last Work Group meeting was on
13	the 25th. We published our White Paper review
14	of Rev 3 in February and now here we are.
15	So what I'd like to take a look at
16	now is just some summary highlights of the
17	Davis and Strom paper since it is a seminal
18	paper that really underlies all these
19	methodologies. What they did was they
20	reviewed six of the HASL reports covering five
21	sites. There were three involved in uranium

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

23

one thorium and one 1 production, radon and 2 There were a total of 63 job titles thoron. 3 for which the DWEs were reported. Each title was held for one to 12 employees. 4 There was a 5 total of 165 employees over a 7-year period. 6 Anywhere from one to 13 operations per job. 7 Each operation would be characterized by up to So you have a total of about 428 8 27 samples. 9 air samples that were analyzed for this study. 10 It's also kind of interesting to note that 11 about 65 percent of these workers were exposed levels maximum 12 to above the allowable 13 concentration which I believe was about, let's 14 see, before 1963 was 70 dpm per cubic meter and after '63 was 100 dpm per cubic meter for 15 16 alpha values at least.

They focused on the variability in the observations that was evidenced in the air sample data themselves. The idea was to generate an uncertainty analysis that could then be used in EEOICPA to assist in dose

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

24

1	reconstruction. They really needed to get an
2	idea of what type of distributions are we
3	looking at and what are the GSDs. What's the
4	best characteristic of the uncertainties. And
5	the main sources of uncertainty are
6	variability in the data, what are the particle
7	size distributions, process variability,
8	placement of the air samples, changes in
9	ventilation, you know, the kind of things
10	you'd expect. And there was also
11	uncertainties basically in whether the samples
12	were representative of actual worker
13	exposures. They also identified what they
14	called blunders. Doesn't mean it was a
15	stupidly performed task, it just meant that
16	there were mistakes made, mathematical errors,
17	transcription errors, things of that nature.
18	And it turned out that these were fairly
19	significant in their study.

21 simulation to generate distributions of

(202) 234-4433

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

25

1 discrete DWEs as well as log-normal fits to 2 And what they did was they'd just the DWEs. 3 go through and for each of those tasks for discrete distribution they'd go through it for 4 5 each run, they'd pick at random one of the multiplied by the time and generate a 6 AACs 7 DWE. And they'd go back and do this 10,000 times and generate that alpha distribution. 8 9 Typical Monte Carlo techniques.

10 The fits, the log-normal fits of 11 course are more claimant favorable typically because they allow for the possibility of 12 13 exposures that were larger than the actual 14 And as you can see because of measurements. the data limitations that's going to be pretty 15 16 important. They found the upper 95th 17 percentile of the GSDs for their data were about 4. The 99th percentile is between 7 and 18 And so that lends support to the use of a 19 8. 20 GSD of 5 when a concentration measurement is available information 21 but there's no on

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

26

1 uncertainty.

2 indicated that They usinq the 3 distribution of air samples without timeweighting or assignments to jobs didn't really 4 5 produce a DWA or any kind of a value or GSD 6 that's representative in any given worker. 7 They noted that the median of the unweighted site-wide distribution was typically higher 8 than the DWAs for all the workers except for 9 10 three. So of all those 63 job types, only them exceeded the median of 11 three of the unweighted distribution. And they indicated 12 13 finally, it was kind of a critical point here, 14 the site-wide average is really, you know, while it is a biased estimator of exposure it 15 16 could be used in making compensation decisions and those would be required to be favorable to 17 the claimant. 18

Take a look at the NIOSH DWE White
Paper Rev 3. Basically you can distill this
down to five different bits of guidance here.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

27

1	Now one is that they propose to use the DWE
2	data to estimate chronic daily intake rates
3	for exposed workers. They assign a DWE for
4	the job description with the highest DWE in
5	the plant where the material was handled for a
6	specific year to every worker in that plant
7	with a GSD of 5. So you take - you look at
8	that whole distribution of GSD - or of DWEs,
9	you take the highest one, the most highly
10	exposed job type. They assign that to
11	everybody in the plant and they use this GSD
12	of 5 for uncertainty. So you have a situation
13	where you've got - essentially you do have a
14	plausible intake for certain workers, for the
15	most highly exposed workers because you're
16	using their data. These were actual
17	measurements for those breathing zone samples.
18	And then you're using the GSD of 5 from Davis
19	and Strom. And so you have kind of a shortcut
20	method that's based on a fairly rigorous
21	analysis. And this obviates the need to go

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

28

1	through for every single site and analyze
2	data, generate your own distributions and then
3	go through that. At the end of the day you're
4	going to come up with something that's not all
5	that different from a GSD of 5.
6	For situations where the data are
7	judged to be inadequate or incomplete they
8	propose to use a high DWE from adjacent year
9	again with a GSD of 5. And then they propose
10	to use the 95th percentile of the unweighted
11	air sample when time-weighted average data are
12	not available. And then finally they
13	recommend to the dose reconstructor to search
14	the SRDB if they have reason to believe that
15	exposures have taken place that are not
16	identified in the existing data sets.
17	And our particular - or the point

And our particular - or the point 17 we come to after two years of discussions and 18 White Paper exchanges is that we - we accept 19 White Paper. 20 NIOSH's latest Revision 3 is scientifically sound and claimant-favorable. 21

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

29

1	However, there is about - there are three
2	technical issues that we feel still need to be
3	resolved. First involves this issue of
4	blunders in the raw data. In Davis and Strom,
5	I believe there were 16 out of 63 of these
6	sets where you had blunders that resulted in
7	either a high or a low measurement by greater
8	than 20 percent. In most cases where the
9	significant blunders did occur they caused
10	twofold underestimated exposure and the worst
11	case was a factor of 10. So you can see
12	they've got an absolute worst case where
13	you've got a factor of 10 underestimate and
14	you throw a GSD of 5 on it you're still
15	underestimating by a factor of 2. Now granted
16	that's a pretty unlikely event but it was seen
17	in this particular analysis. And we feel that
18	the DWE data should be validated for a
19	particular site just to identify the frequency
20	and magnitude of blunders that may have
21	occurred in the raw data transcription and

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

30

1 calculations.

We also feel that NIOSH should be 2 3 using the 50th percentile of unweighted air sample data when DWEs for adjacent years are 4 5 not available. And that was called out right 6 there in the Davis and Strom paper that the 7 50th percentile, I mean you captured 60 out of the 63 job DWEs by just using 50th percentile. 8 And in our paper, in our review of Rev 3 9 10 we've made an example there. That was for Fernald, I think the highest thorium exposure. 11 You had a situation where the - they took the 12 worst sample which occurred for I think it was 13 scrubbing out reduction pots in the metals 14 reduction. I can't remember exactly what it 15 16 was. You had a value of about a million dpm this is 17 cubic meter and a short-term per incredibly dusty operation experienced by a 18 few workers in a very short period of time. 19 20 And if you take that and apply it to everybody it just kind of goes against the concept of 21

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

31

1 plausibility. mean, eventually you Ι qet 2 something that's bounding but is it really 3 plausible. Is this something that any particular could 4 worker have actually 5 experienced. So we feel that the 50th percentile is probably a better number to be 6 7 using. Finally, we feel that the TBD should make available the necessary DWE data. 8 We 9 think that's an undue burden on the dose 10 reconstructor to go looking for more data and it could result in inconsistencies from case 11 12 to case.

Finally, if you'd like to go ahead 13 14 and get out the handout that Ron provided, on page 39 it kind of gives you a little bit of a 15 16 description here and section 6.1.3, Airborne Dust Studies. And they introduced a different 17 concept here for the uranium data at least 18 where they used what they call a DWA index. 19 20 And so what they did was because workers - and a given worker rotated through the job they 21

NEAL R. GROSS

(202) 234-4433

32

1	did a secondary weighting by manpower
2	allocation I believe is the word they use
3	here.
4	DR. BUCHANAN: Excuse me just a
5	minute, John. This is Ron Buchanan, SC&A.
6	What we're looking at for those on the phone
7	is page 39 through 45 of NIOSH's ER report
8	that lists the uranium and thorium air
9	concentration measurements at Weldon Spring.
10	Okay, sorry, go ahead John.
11	MR. STIVER: Oh, that's fine.
12	Yes, I kind of got ahead of myself on that.
13	This is the SEC ER report 143, page 39, just
14	at the bottom of that page. And the last line
15	there is the interesting thing because they
16	indicate that some of the raw data are
17	actually available and also provide a
18	reference for that which I've listed, a
19	Mallinckrodt publication in 1966. It's
20	entitled Summaries of Dust Concentrations at
21	Production Jobs, Life of Operation from Year

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

33

1	1957 to 1966. I believe that's in the SRDB.
2	It would certainly be easy enough to find.
3	Let's take a look at the uranium
4	data. This was on page 40 of 92. And you see
5	what you have here is you've got data for 10
6	different plants. This is a uranium
7	production facility so it's set up pretty much
8	the same as Fernald was. You had sampling
9	plants, digestion, a refinery. You had green
10	salt production where the tetrafluoride was
11	produced and you had the metals plant where
12	the tetrafluoride was reduced to metal. You
13	had chemical pilot plants and scrap plants.
14	So it's set up the same way. There are
15	anywhere from four to 11 job titles per plant,
16	a total of 78 job titles, and the data go from
17	1958 to 1966. Like I said, the number of
18	workers in the summary table are not provided
19	but I believe that type of information would
20	be in the source data. Most of the job titles
21	here you can see, if you look at the key here,

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

34

some of them didn't - because there weren't enough workers for a particular task they just reported the DWA, they didn't use the DWE index.

And if you look down, the second 5 to last row, chemical - the pilot scrap plant, 6 7 if you look at the worker title which is the third column over. 8 You see that there's various - there's values, a little superscript 9 F and these, basically what they did is they 10 used the median unweighted air concentration 11 because they didn't have the time-weighting 12 13 for that. This is an example of what we were talking about earlier of when you don't have 14 the data. What they did, they chose to use 15 16 here was to report the median value.

17 Summary, you can see there's no 18 data provided for 1957 for any of the plants 19 and the most comprehensive data sets are for 20 the sampling plant and the green salt plant. 21 From 1958 to 1965, a pretty robust data set

NEAL R. GROSS

(202) 234-4433

35

1	there. And the most sparse data are found for
2	the metals core area, that's building 301. We
3	only have data for 1960. However, you do have
4	data other than for 1958 for the other
5	portions of the metals plant. So you have
6	data from different areas within the metal
7	plant. And that's another thing that Davis
8	and Strom pointed out was that the - just to
9	digress a little bit - that the uncertainty
10	within a given area in time was typically
11	greater than the uncertainty between areas.
12	And so using data from another portion of the
13	plant may be appropriate, especially given the
14	uncertainty values that are assigned here.
15	And in this case you've got the reduction
16	operations which are - you can see the values
17	here are the highest. So if those are being
18	applied then to the core area you can be
19	pretty reasonably sure that you're assigning a
20	bounding value. You can see there's gaps of
21	from three to six years for the core area and

NEAL R. GROSS

(202) 234-4433

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

36

1	the pilot scrap special projects plant. And
2	the others you have missing single years. So
3	you have a situation where all the different
4	aspects of Rev 3 come into play here.
5	And let's take a look now, the
6	next few tables here, table 6-5 of the thorium
7	data and we have a lot better granularity in
8	this data set than we had for Fernald, that's
9	for sure. You have - basically you have the
10	same type of situation you had at Fernald
11	where you've got short-term campaigns. And
12	you can see if you go down, column 5 time
13	period. This gives you the idea, it tells you
14	when those particular operations were going
15	on. And then over here in the notes column
16	it'll tell you what the test date was. So
17	look at that first set of data in table 6-5
18	Sampling 101. This first line, oven-drying
19	thorium oxide in the pan transfer. This took
20	place in March of '65 and you have one day,
21	March 20, 1965 where they did the air

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

37

1	sampling. And you also notice in the notes
2	column that they give you a lot of information
3	here. They give you the manpower allocation
4	to thorium work for some of the jobs and they
5	identify when the airline masks were
6	prescribed and worn.
7	So you have a pretty robust data
8	set here. You can see the highest DWAs,
9	that's something we pointed out in our report
10	for Fernald. So it's the re-drumming or the
11	repackaging of the thorium. And you see that
12	I believe is on the second, the next page here
13	on page 44, bottom of that first table,
14	repackaging thorium oxide and recast. This
15	was the metals area. And you got the highest
16	value, 2,060 dpm per cubic meter.
17	DR. BUCHANAN: It's page 43.
18	MR. STIVER: Yes, excuse me, page
19	43. My mistake. I just got a summary output
20	here. And so you'll see the notes along the
21	side here that tell you what was going on,

NEAL R. GROSS

(202) 234-4433

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

38

1	when	the	sample	es wei	re	collect	ed a	and	the	test
2	days.	S	o you	have	a	pretty	sol	id	data	set
3	here.									

4 So I guess in summary what we can 5 say is that if there are any issues here with uranium it's - with the metals area, the core 6 7 area, you'd have to use data from other parts of plant 301. The pilot scrap plant, I would 8 9 think that the 50th percentile of the 10 unweighted distribution would be appropriate 11 for that area. The qaps in the special would 12 projects require professional area 13 iudament whether to use the mavbe the 14 highest - go back to the uranium data. The 15 highest DWA here was 320 in '63. So there'd 16 be a question. You've got a gap of - from '58 17 to '62 there's no data there so would you assign the highest of that set to that value 18 or would you use the 50th percentile. 19 This 20 will be something that would require some professional judgment on the part of the dose 21

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

39

1	reconstructor. It should be provided in the
2	TBD. For thorium, like I said, the
3	granularity appears to be pretty good and I
4	would think that a GSD of 5 would adequately
5	address the uncertainty.
6	And that's really all I have to
7	say. I guess if anyone has any questions or
8	comments I can entertain those.
9	DR. BUCHANAN: Okay. So your
10	bottom line down there is saying that the main
11	issue would be to do some verification of the
12	raw data.
13	MR. STIVER: Really, yes. I think
14	that probably the one thing that still needs
15	to be done is some sort of a validation
16	exercise. It wouldn't have to look at every
17	single report or every single piece of paper
18	in the raw data, but certainly some kind of
19	sampling could be done that would give you
20	some kind of reasonable confidence that you've
21	got a decent handle on the frequency and the

NEAL R. GROSS

(202) 234-4433

40

1	magnitude of the blunders such as they exist.
2	Without even looking at it all I think you've
3	got this additional source of uncertainty
4	there that could really potentially
5	underestimate your intakes.
6	DR. BUCHANAN: Okay, thank you
7	John. Questions on - in the room or on the
8	phone?
9	MR. ROLFES: John, when you - this
10	is Mark Rolfes. When you had mentioned the -
11	there were a couple of factors that the
12	blunders resulted in under- and overestimates.
13	You had quoted a factor of 2 for the
14	underestimate and then also quoted a factor of
15	10. So -
16	MR. STIVER: That was the worst
17	case scenario. They had one value that it was
18	an underestimate of 10. I believe it was a
19	time. They put in the wrong time value.
20	MR. ROLFES: Okay. I wasn't sure
21	if that was an overestimate or underestimate.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

41

1	MR. STIVER: That was an over.
2	You had others that were underestimates - or
3	overestimates. The worst - the most probable
4	was an underestimate of 2 and the worst case
5	was an underestimate of 10.
6	MR. ROLFES: Okay.
7	MR. MORRIS: This is Robert
8	Morris. Can I?
9	MR. KATZ: Yes, Robert.
10	MR. MORRIS: I was - wanted to go
11	to closure on whether or not this is an SEC
12	issue at this point or a TBD issue at this
13	point.
14	MR. STIVER: For this particular
15	site and for Fernald I think this is more than
16	a TBD issue at this point. That would be my
17	particular - that would be my opinion.
18	MR. MORRIS: That's my impression
19	of what we had agreed to on a prior call but I
20	wanted -
21	MR. STIVER: Yes, when we did I

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

42

1	think it was the April meeting and also the
2	February meeting for Fernald. So we came to
3	that conclusion.
4	MR. MORRIS: But we do have this
5	blunders evaluation on our schedule.
6	MR. STIVER: Yes, the blunder
7	evaluation I think is the final thing that
8	needs to be done here.
9	DR. MAURO: Yes, this is John
10	Mauro. That's correct. For Fernald we really
11	have gotten to the point where we think that
12	our position is to recommend that this be
13	treated as a Site Profile issue. We see sort
14	of like the light at the end of the tunnel on
15	how this could be resolved, especially this
16	blunder issue. So, and I think what I'm
17	hearing from listening it sounds like this is
18	a very similar situation you have here with
19	Weldon.
20	MR. STIVER: Yes.
21	DR. BUCHANAN: Okay, thank you

DR. Okay, thank you **BUCHANAN:**

> **NEAL R. GROSS** COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

43

1	John, both Johns. Appreciate you being on the
2	phone. Wanted to get this off, completed
3	first. Chairman, do you have any further
4	questions or issues on this issue?
5	CHAIRMAN GIBSON: So are we going
6	to keep this open as a Site Profile issue for
7	Weldon Spring as well until it's resolved?
8	DR. BUCHANAN: Yes, I think that
9	the check for blunders, mistakes and posing
10	the information would be a Site Profile issue
11	as far as the methodology. Looks like it can
12	be taken off the table as far as an SEC issue.
13	MR. FITZGERALD: As a matter of
14	efficiency - this is Joe - it sounds like we
15	have the same people working the issue between
16	Bob Morris and people like John Stiver so it
17	just sounds like in concert with the
18	resolution for Fernald the TBD-scoped
19	resolution for this would certainly be, hand
20	in hand would be something that would be
21	important all together.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

44

1	CHAIRMAN GIBSON: So do we have
2	any kind of time idea when this might be put
3	to rest or?
4	DR. BUCHANAN: John? John? I
5	mean, I guess Bob.
б	DR. MAURO: Yes, let me help out a
7	little bit with that. I know our St. Louis
8	meeting is coming up and I know that there is
9	some discussion going on regarding Fernald.
10	And you know, there are issues that are Site
11	Profile issues and there are some very serious
12	SEC issues. The strategy and certainly Ted
13	could weigh in as to the thinking here, but
14	when we have moved to a place where there is
15	an emergence of - it looks like a judgment is
16	taking form that there might be an SEC issue
17	before us and perhaps even granting some SEC
18	for some time period the Board and the Work
19	Group usually says okay, though we have not
20	resolved many issues and in fact many issues
21	may be unresolved and on that borderline area.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

45

1 say they're in a borderline area on Let's 2 whether they might be - I'm sorry, SEC or Site 3 Profile issues. Nevertheless, if it becomes clear that there are certain issues that are 4 clearly unresolvable SEC issues I notice that 5 the Work Groups will start to zero in on those 6 actually 7 and start to move forward with perhaps a recommendation for that. 8 Without closing the door on possibly expanding the 9 10 Class at some point in the future if it turns out that what appears to be a Site Profile 11 issue may be in fact a more serious SEC issue. 12 13 So Ι mean, Ι hope Ι characterized that properly and Ted, I'll defer to you on these 14 kinds of judgments. 15

16 MR. KATZ: Well, I mean I think Weldon Spring and Fernald are different. 17 Like I said, they have this common issue but in 18 other ways they're quite different. 19 I mean 20 Fernald, we have reporting out on Fernald. We've been trying to report on that for awhile 21

NEAL R. GROSS

(202) 234-4433

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

46

1	actually and been working up towards that.
2	And because it's a big and complex site we
3	wanted to sort of lay a lot of groundwork with
4	the Board which is why we started the
5	reporting out actually in the last meeting,
6	we're going to do some more in this meeting,
7	so to bring the whole Board up to speed not
8	just on one issue but on a number of issues.
9	So I'm not sure what I'm
10	summarizing about what you said, about whether
11	- I mean, the Work Groups report out when they
12	feel like they've taken their issues as far as
13	they can bring them whether they have
14	clarified that they have an SEC recommendation
15	or not and in a number of cases the Work
16	Groups actually don't have necessarily an SEC
17	recommendation. They have sort of I think
18	like you were saying, John, this sort of gray
19	area where they have some difficult issues and
20	they think they've brought them as far as they
21	can and they're ready for really, for the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

47

1	whole Board to engage and dig a little deeper
2	as a Board. So.
3	MR. FITZGERALD: Yes, John?
4	DR. MAURO: Yes.
5	MR. FITZGERALD: Joe. Just to
6	clarify for Mike's benefit. I think the
7	question is as far as time frame on this,
8	settling the blunders issue and I think what
9	we're saying is similar to Fernald it's
10	certainly tilting toward more of a TBD/Site
11	Profile context.
12	DR. MAURO: Yes.
13	MR. FITZGERALD: But I know you're
14	trying to resolve the very same issues with
15	Fernald and I suspect these will be joined in
16	the sense trying to figure out how to deal
17	with blunders. Is there any time frame on
18	that front? You know, understanding that yes,
19	there's some pressing SEC matters.
20	DR. MAURO: I mean to me in my
21	mind if we try to create an analogous

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

48

1 situation which could be helpful is it's clear 2 that the world of issues that we have engaged 3 on Fernald have come down to one particular 4 issue that may or may not emerge as an SEC 5 that perhaps the Board is going to have to address very seriously as a possible SEC for 6 7 Fernald. All the other issues have been put, 8 Ι would have say have been either to tentatively resolved with maybe 9 some minor 10 A couple of them are a little bit mop-up. more serious but still within the realm that 11 perhaps they could end up being something that 12 13 would cause an expansion of a – the SEC 14 definition of the Class. So I if mean, there's an analogous situation I would say the 15 16 blunder issue in the case of Fernald is 17 clearly being placed in a box that we'll say we're going to put this in the Site Profile 18 and we're going to leave it in the parking lot 19 20 and not worry about it right now until we come to grips with the - what we consider to be 21

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

49

1	very serious SEC issues and try to get closure
2	on those which may end up meaning, you know, a
3	recommendation for an SEC for a particular
4	time period without closing the door on these
5	other issues. But the other issues I have to
6	say have waned into the background. Many of
7	them either have been resolved, actually
8	formally resolved and everyone agreed to close
9	the issue that's been resolved. There have
10	been a number of those on Fernald. But there
11	were also a number in the gray area that we're
12	calling Site Profile issues and there's
13	general agreement and we've put those what I
14	call in the parking lot while we zero right in
15	on the ones that everyone knows are the hot
16	SEC issues. That process means unfortunately
17	that we don't have a schedule for closure of
18	the blunder issue and it puts you folks in the
19	same position.
20	MR KATZ: Well I think. I thought

20 MR. KATZ: Well I think, I thought 21 I heard Robert say that ORAU has - is going to

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

50

1	be working on the blunders issue and analysis
2	of that isn't it? Didn't I hear you say that,
3	Robert?
4	MR. MORRIS: Yes, that's true, it
5	is on our - it's on our work chart, the - what
6	we used to call the Gantt chart.
7	MR. KATZ: Right, so I guess the
8	question right now is really it's not really
9	in SC&A's ballpark right now, it's in yours to
10	move this forward. Do we have a sense right
11	now at least where is it on the Gantt chart
12	right now in terms of you doing an analysis of
13	this?
14	MR. MORRIS: Well, I don't have my
15	Gantt chart open right this minute. I'm
16	thinking that it's the end of this month.
17	MR. KATZ: Oh, okay. So
18	relatively short term.
19	MR. MORRIS: Monica, have I got it
20	right?
21	MS. HARRISON-MAPLES: I'm not sure

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

51

1	because that's a Fernald issue. I mean, it's
2	not on the WSP part of the Gantt chart I don't
3	believe at this point.
4	MR. MORRIS: I think it is.
5	MR. ROLFES: This is Mark Rolfes.
б	And at the Fernald Work Group meeting we were
7	asked to address the SEC-related issues
8	primarily first and then with the second set
9	of issues being the TBD issues. So you know,
10	without getting out the Gantt chart and
11	discussing our specific, you know, dates that
12	we've got planned right now let's, you know,
13	we can probably put something together I'm
14	thinking within a matter of a month or so,
15	but.
16	MR. KATZ: Okay, so let's just
17	have an action item for - DCAS can sort out
18	its scheduling and give us a note by email
19	just letting us know where this falls out in
20	their schedule.
21	MR. FITZGERALD: Sounds like the

52

1 consideration just important _ Ι iust 2 overheard Monica say something about WSP not 3 being sort of on there with Fernald on this particular issue. It sounds like it would be 4 5 useful just to make sure Weldon is listed along with Fernald for this issue on whatever 6 7 scheduling so that it's clear that it's feeding two sites as far as information. 8

9 the important take-home Ι quess 10 message is that as with Fernald this is more in the Site Profile context and it would be 11 handled in concert with the analysis that's 12 13 being done on this issue with Fernald. But it is program and will be done in the relatively 14 15 short term.

MR. STIVER: This is John Stiver. I'd like to make one extra comment here. I think we also need to be cognizant of the issue of the site-specific data. So whether this is resolved for Fernald and Weldon Spring we'll be looking at two different data sets

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

53

1	and so it may turn out to be more of an issue
2	for one or the other.
3	MR. KATZ: Good point, John.
4	MR. STIVER: We need to keep that
5	in mind as well.
6	MR. ROLFES: Yes, that was one of
7	the concerns with the petitioners as well
8	that we focus on Weldon Spring data rather
9	than on Fernald data for the discussion of the
10	Weldon Spring Plant SEC evaluation. That's
11	what we tried to do and we've tried to keep it
12	separate to address that concern.
13	CHAIRMAN GIBSON: I just want to
14	keep on the schedule because I want to keep
15	moving. I don't like these parking lot
16	issues. They seem to just kind of -
17	MR. ROLFES: Languish.
18	CHAIRMAN GIBSON: - get behind a
19	lot of things.
20	MR. STIVER: They do. This is
21	John. You're absolutely right. I've seen it

54

happen. It's so easy to focus in on the SECs and once something happens there we sort of forget that, wait a minute, we still have a lot of things to deal with. You're absolutely right.

6 MR. FITZGERALD: It may be better 7 just to keep them separate then. Sounds like. is 8 DR. BUCHANAN: This Ron 9 Buchanan, SC&A. We approached That's true. 10 the generic issue of DWE because it was going on at Fernald and we didn't want to waste 11 resources redoing it at Weldon Spring. 12 But I 13 think at that point it stops. We've agreed to methodology, the science behind it is set but 14 the actual data set is a completely separate 15 16 issue with Weldon Spring. So addressing its correctness is a different 17 for issue than 18 Fernald. We can't say that Fernald was 19 correct, that doesn't mean that Weldon Spring. 20 So definitely we want to do the Weldon Spring as a separate issue as far as accuracy of the 21

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

55

1	data that's being used in this model.
2	DR. MAURO: This is John again.
3	Let me add to that a little bit. The process,
4	the thinking that goes into it, that they want
5	you to go through some data evaluation on
6	blunders for Fernald which is on your Gantt
7	chart. I think that the strategy that's
8	adopted for dealing with the problem, let's
9	say you make a determination that this percent
10	of the data were, you know, mistranscribed and
11	could have had an effect on some small but
12	real number of people, could have been
13	underestimated by a factor of 10 or whatever
14	it is. You know, wherever you come out on it.
15	The big question is going to be okay, how do
16	we factor that into the dose reconstruction
17	process to make sure you have a coworker model
18	in effect that - which is what we're building
19	here, that factors that in. That's going to
20	be very interesting and I think something - so
21	the process, the thinking that goes in is

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

56

1	going to be very valuable and of course will
2	be transferrable to Weldon which would make it
3	clearly - and once it's all agreed that yes,
4	that's a good way to deal with the blunder
5	issue. Then it becomes a matter of applying
6	that same methodology to Weldon Spring. So
7	it's almost a two-step process.
8	MR. MORRIS: Ted, this is Robert.
9	MR. KATZ: Yes, Robert.
10	MR. MORRIS: I think I
11	misunderstood. We have that as a task on our
12	Weldon Spring work effort. We're not talking
13	about validating for Fernald right now, we're
14	talking about validating for Weldon Spring and
15	it's scheduled in my older notes that I've got
16	here at the end of this month.
17	MR. KATZ: That's how I understood
18	you. Thank you, Bob.
19	MR. STIVER: John Stiver. As John
20	was saying, I mean, it could go either way.
21	As long as you develop a methodology for one

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

57

1	of those sites which would then be applicable
2	for the other at the time horizon.
3	MR. MORRIS: Well, and I guess the
4	other thing that I'd say in response to what
5	John just said, how do we factor in - whether
б	it's small or large, how do we factor in the
7	finding unless the - never anything is ever
8	observed. So I think you have to say a GSD of
9	5 is a pretty doggone generous assumption in
10	most cases and it was probably bounded unless
11	we find some real outliers.
12	MR. STIVER: It would be a matter
13	of factoring it into the overall uncertainty
14	term and whether that - would that GSD of 5 be
15	accurate would be a statistical issue.
16	DR. MAURO: And that would be one
17	approach to dealing with this that I, you
18	know, certainly it should be entertained by
19	the Work Group.
20	MR. MORRIS: Well anyway, I think
21	we'll deal with that and if it's obvious that

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

58

1 the blunders are obvious and important in 2 it's rounding scale, whether errors and 3 mathematics did the know, we do or you 4 arithmetic wrong, those are two different 5 kinds of questions and so I think it remains 6 to be seen how we answer that question you 7 raised, John.

8 DR. MAURO: Let ask me you 9 Once - I'm trying to deal with something. 10 this. Once you say that, okay, here is all the data and a couple of places where there 11 12 was a blunder. Then do you - and maybe I'm 13 not thinking right about this, but you could 14 fix the blunder and then go back and say here's what the results would have been if you 15 16 didn't have the blunder.

17 MR. MORRIS: Of course you can and that's - that's a possibility. If there are a 18 lot of blunders it raises the question of how 19 20 extensive does sampling have your to be. Maybe you would fix the blunder and say well, 21

NEAL R. GROSS

(202) 234-4433

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

59

1	it made a 0.01 percent difference in what our
2	dose reconstruction for thorium intake would
3	have been. And so you go, well, these
4	blunders were not important in the overall
5	picture and so maybe we can just relax on the
6	rest of them. But if the blunders had a
7	really significant change on the outcome of
8	the dose reconstruction then you'd have to say
9	well, let's go look farther and harder.
10	DR. MAURO: So you could see why
11	you would consider this to be a Site Profile
12	issue. There are strategies for wrestling
13	this problem to the ground some of which are
14	easier and some of which are more difficult,
15	but in our opinion it's doable. And you know,
16	and how that fix will actually be implemented
17	might differ on Weldon and Fernald, but in
18	both cases they seem to be tractable.
19	
	MR. MORRIS: I agree with you.

21 well.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

www.nealrgross.com

60

1	MR. KATZ: Okay.
2	DR. BUCHANAN: Okay. So I think
3	we've reached a conclusion on that. Do we
4	want to break or do you want me to continue?
5	CHAIRMAN GIBSON: Go ahead.
б	DR. BUCHANAN: Okay. I didn't
7	know. Okay. So we had four action items,
8	that was number one, and we - so that brings
9	us up to speed on DWE. Okay, number two was a
10	recycled uranium question. I had brought up
11	the fact that - that to bring - kind of get a
12	summary, bring everybody up to date is that
13	recycled uranium was introduced at Weldon
14	Spring in the '60s and so it can contain more
15	impurities of course than the uranium ore so
16	it invades the contaminant of radioactive
17	material. And usually it's around 2 to 10
18	percent parts per billion of plutonium for
19	uranium. And so the - the Weldon Spring TBD
20	said that 100 parts per billion of plutonium
21	for uranium would be a sign to the workers as

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

61

1 a bounding amount. And so we agree that this 2 is probably a reasonable intake to assign and 3 would anybody would take cover what in. went back and did some 4 However, we claim analysis and I did five claims and I could 5 6 only find one where they had actually added in the 100 parts per billion of plutonium for 7 uranium. 8

And so I sent that information to 9 10 NIOSH on the second of February, those five claim numbers, and so what I'd like to do is 11 wait until they give their response and see. 12 13 The main issue here is okay, we agree the 14 methodology is okay, but is it being applied. Is this limiting 100 parts per billion being 15 16 applied in actual dose reconstruction. So 17 that was item number two we responded to. 18 Item number three was -19 CHAIRMAN GIBSON: So on item

20 number two then, so DCAS, when do you think21 that you'll have that response ready for SC&A?

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

62

1	MR. ROLFES: As far as a date I
2	couldn't tell you honestly. We've been trying
3	to get some of the bigger issues addressed
4	right now and this is more of a claim-specific
5	issue at the moment. I haven't had the
6	opportunity to look at these claims. I do see
7	what SC&A has provided here. Monica, do you
8	have any feel? I don't have a copy of the
9	Gantt chart here in front of me. We were
10	provided a list of five claims for which SC&A
11	looked at to determine whether or not the type
12	of contaminants were applied. They found one
13	of them did have the default 100 parts per
14	billion plutonium on a uranium S basis
15	applied. The other four did not. I haven't
16	looked at those four cases to see possibly if
17	we used some other, like an OTIB-2 approach or
18	something for example. I don't know. Do you
19	recall, Ron, if that might have been the case?
20	DR. BUCHANAN: It's been awhile
21	but I don't believe so at least for job

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

63

1	titles. I picked out five job titles,
2	chemical operators and stuff that you'd expect
3	and I didn't analyze - go through all the dose
4	reconstruction in detail but I didn't see
5	anything that jumped out and said well, this
6	is the reason they weren't assigned the
7	plutonium from the TBD. And so anyway, that -
8	SC&A responded and that's where it sits as far
9	as our action item goes.
10	MR. ROLFES: So Monica then I
11	don't know if you could give me a quick update
12	if you might know the answer?
12 13	if you might know the answer? MS. HARRISON-MAPLES: I don't know
13	MS. HARRISON-MAPLES: I don't know
13 14	MS. HARRISON-MAPLES: I don't know the answer offhand. I can get with you after
13 14 15	MS. HARRISON-MAPLES: I don't know the answer offhand. I can get with you after this call. I'll find out the answer and get
13 14 15 16	MS. HARRISON-MAPLES: I don't know the answer offhand. I can get with you after this call. I'll find out the answer and get it to you.
13 14 15 16 17 18	MS. HARRISON-MAPLES: I don't know the answer offhand. I can get with you after this call. I'll find out the answer and get it to you. MR. ROLFES: Okay, thank you.
13 14 15 16 17 18	MS. HARRISON-MAPLES: I don't know the answer offhand. I can get with you after this call. I'll find out the answer and get it to you. MR. ROLFES: Okay, thank you. MS. HARRISON-MAPLES: You're

64

1	the most important issue we're dealing with
2	and have been dealing with, and certainly Mark
3	Rolfes is well aware of the discussions we've
4	had. I just have a question for you that
5	maybe others might have on their minds also.
6	Did Weldon receive any of this special
7	material that is referred to as either tower
8	ash or the CIP/CUP material directly from
9	let's say Paducah or did they - did Weldon
10	just get down-blended, material that was
11	already down-blended at Fernald and then
12	shipped from Fernald to Weldon?
13	MR. ROLFES: John, the answer
14	regarding, you know, the shipment of the
15	highly contaminated transuranic containing
16	uranium materials from the Paducah facility or
17	the other gaseous diffusion facilities, none
18	of that material was ever sent to Weldon
19	Spring. It was only sent to Fernald and it
20	was only sent really in a couple of shipments
21	in the mid-'70s and early '80s.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

65

1	DR. MAURO: Very good. That's
2	what I thought but I wanted to confirm. The
3	second thing, Mark, as you remember, one of
4	the fixes dealing with one of the concerns and
5	John Stiver could speak to it in greater
6	detail, but and we want to sort of step back
7	and look at the big picture, the business of
8	the bomb reduction and the dolomite. As you
9	know, one of our concerns was that as you did
10	that process and reused the magnesium fluoride
11	I guess, or that comes out of the process you
12	get a reconcentration of the plutonium in that
13	dolomite and you folks eventually came up with
14	what we considered to be a very good fix.
15	This is one of the subjects we discussed on
16	Fernald and we came to I believe it would be
17	fair to say a general consensus that the 400
18	part per billion number that reflects the
19	assumption that would be used for those kinds
20	of exposures where a person may have been
21	exposed to the airborne uranium that is

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

66

1	associated with the bomb reduction process and
2	the dolomite might very well have as much as
3	400 parts per billion as opposed to 100 parts
4	per billion. I know you folks have offered
5	that up as a way to deal with that scenario
6	for Fernald. Do you have a similar
7	circumstance for the reduction process going
8	on at Weldon?
9	MR. ROLFES: Well, to address what
10	you said previously we didn't observe up to
11	400 parts per billion in that magnesium
12	fluoride, it was only up to - it was around 96
13	parts per billion I believe which was still
14	under our 100 parts per billion default.
15	DR. MAURO: Okay, and you're
16	saying that's at Weldon now?
17	MR. ROLFES: No, no, this is at
18	Fernald.
19	DR. MAURO: Okay, then I
20	misunderstood. I thought that there were a
21	large number of samples of this material

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

67

collected. John, you can help me out a
 little.

3 John, this is John MR. STIVER: Yes, when you look at the source data 4 Stiver. that came out of the DOE Ohio Field Office 5 reports they had about 400, a little more than 6 7 400 samples for the dolomite for plutonium. And what NIOSH proposed was to do a log-normal 8 fit on that data and then take off the 95th 9 10 percentile. And that's where the 400 parts 11 per billion comes from.

12 DR. MAURO: Oh, okay.

13 MR. STIVER: And then our point is 14 really look the feed that you can't at concentrations because at Fernald, 15 material 16 for example, even though this material came in, the CIP/CUP residues in the '70s and the -17 the POOS material, the tower ashes in 1980 18 which is the biggest one, that material was 19 20 down-blended on the front end, at plant 1 and plant 4 before it ever even went into the 21

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

> > 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

68

1	refinery. So what you're seeing going into
2	the reduction area which is the highest
3	concentration of all for all the workers is
4	material that's already been down-blended. So
5	at that point it didn't really matter whether
6	it was CIP/CUP, PTA or the tower ash or some
7	other source, you've got that concentration
8	mechanism. That was our real point is that
9	you can't just look at kind of the more
10	simplistic view of what's coming in in the
11	feeds and set your time periods on that
12	because that's - 400 is probably a good number
13	to bracket the - or to bound the potential
14	intakes of the plant 5 and also the plant 1
15	mill rise people that, you know, reconstituted
16	the dolomite for reuse. And that's that
17	subgroup, the most highly exposed subgroup.
18	And so we were saying oh that 400 is a good
19	number, but it's a good number all the way
20	back too, not just for the '70s. But then
21	you've got the other issue of this other

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

(202) 234-4433

1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701 www.

69

1	group, you know, the down-blenders.
2	DR. MAURO: Right. But that
3	doesn't exist.
4	MR. STIVER: That doesn't exist
5	for Weldon Spring.
6	DR. MAURO: That's the only -
7	MR. STIVER: Four hundred parts
8	per billion would certainly be applicable at
9	Weldon Spring.
10	DR. MAURO: Okay.
11	MR. STIVER: You're looking at the
12	same type of process.
13	DR. MAURO: Okay. My question I
14	guess and to Mark and to everyone around the
15	table is it sounds to me that one of the
16	strategies that is being considered, and
17	correct me if I'm wrong, at Fernald is to go
18	to a 400 part per billion versus a 100 part
19	per billion base because it's the 95th
20	percentile of those 400 samples. Is there any
21	reason - whatever approach you select, maybe

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

(202) 234-4433 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

70

1	I'll say it a simpler way. Whatever approach
2	you do select regarding RU as your baseline
3	for Fernald, is there any reason why it should
4	be different at Weldon?
5	MR. ROLFES: Yes, and that's the
6	second part of your question that I didn't get
7	to answer before.
8	DR. MAURO: Okay.
9	MR. ROLFES: You can take a look
10	at page 27 of 90 of the SEC Evaluation Report
11	for Weldon Spring. We actually have the
12	maximum recycled uranium contaminant levels
13	within Weldon Spring Plant. And the 95th
14	percentile level of plutonium was 6.3 parts
15	per billion of uranium. So that in comparison
16	to the previous approach that we documented in
17	using 100 parts per billion for Weldon Spring,
18	the actual data upon review showed that the
19	recycled uranium materials process at the
20	Weldon Spring Plant were of lower transuranic
21	contamination.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

71

1	We have a note under this table 5-
2	6 and these bounding values that we reported
3	in the table were calculated as the 95th
4	percentile of an unblended uranium trioxide
5	PUREX source and assuming a log-normal
6	distribution. This provides the highest
7	values for the two subgroups of recycled
8	uranium like we received by Weldon Spring and
9	this comes from DOE 2000.
10	DR. MAURO: Very good. Thank you
11	very much.
12	MR. STIVER: This is John Stiver.
13	There's still one little thing that kind of
14	bugs me. This is once again, what you're
15	looking at at 6.3 is the feed material
16	concentration. It's not really the magnesium
17	fluoride concentration. It wouldn't be of
18	concern for the metal workers. So I think we
19	kind of still have the same problem here that
20	we have at Fernald.
21	MR. ROLFES: Okay. I actually

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

72

1	received a White Paper on recycled uranium.
2	Well, I haven't received it yet but it's
3	sitting in my office. So I haven't had the
4	opportunity to review the most recent response
5	on recycled uranium. I don't know if anybody
б	on the line, either Bob, Bryce or Monica might
7	have any details or updates for me as the
8	status of our response on recycled uranium at
9	Weldon Spring.

10 MR. RICH: This is Bryce, Mark. We looked at this again and using some Fernald 11 12 data, primarily operational subgroup 6a which is the recycled uranium directly from Hanford 13 to its being down-blended at all and 14 prior 15 that from mainly the material, was а 16 representative material that went to Weldon And that, the 95th percentile is in 17 Spring. billion 18 the 7 parts per range. So the Spring 19 material that went to Weldon from 20 Fernald and the material that came from the gaseous diffusion plant prior to the time that 21

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

73

1	they sent the - the ash and the tail and all,
2	it was probably in the 10 to 20 parts per
3	trillion. They decided on a foundation factor
4	in the gaseous diffusion system. But we - we
5	need to discuss this just a tad more.
6	MR. ROLFES: Okay. As soon as I
7	have the opportunity to review the recycled
8	uranium White Paper that I just received then
9	we'll send that out to SC&A and the Work Group
10	Members. So if it doesn't specifically
11	discuss this we'll have to work to put some
12	revised information in there so that we do
13	discuss this.
14	MR. FITZGERALD: So really, just
15	to recap, there's two issues. One is the 100
16	parts per billion, but it sounds like this
17	paper will certainly address that issue
18	relative to Weldon Spring anyway. Right now
19	it suggests that maybe the 100 certainly is
20	the conservative value for Weldon. I'm just
21	saying we'll see that.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

(202) 234-4433

1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701 w

74

1	The other issue is the one that
2	you're going to be checking on with Monica
3	which is the sampling that Ron was talking
4	about, whether in fact I guess this factor,
5	this RU factor is being added in on dose
6	reconstructions and if not, why not, and just
7	sort of some feeling for that. I think those
8	are two parts, that issue is in that report.
9	DR. BUCHANAN: Yes, that's
10	correct.
11	MR. KATZ: For clarity for binning
12	things, that second part of the cases that you
13	looked at, I mean that - it's almost like -
14	that's a DR review issue, not even a TBD issue
15	really except how it was implemented, like you
16	said, which is really a reconstruction case
17	review. I'm a little bit - I mean I
18	absolutely should follow it up since you dug
19	into that but it really in a sense, once you
20	get results, unless they indicate there's a
21	technical problem, a TBD, if it's just an

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

75

1	implementation issue it's really an issue that
2	belongs in the Dose Reconstruction
3	Subcommittee's court because they're the ones
4	who worry about the quality of dose compliance
5	with our own procedures and so on. Or I'm
б	missing -

7 MR. FITZGERALD: Yes, Ι think we've done this in other SECs, I think it's 8 just a matter of understanding you know the 9 10 rationale for how the factor is applied, not 11 so much whether it was or wasn't and that part of which you're right, it's a task for dose 12 reconstruction. 13 But just trying to get a 14 of if this the application, sense is understanding the rationale for 15 how the 16 application is used. And it's not clear how 17 it's actually used. And I think that would 18 help. It's not a - I quess the other is a QA 19 function, I agree. That's not what we're 20 doing here. But just understand if we're somehow not comprehending how that 100 is used 21

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

76

1	in this application, it's just a puzzle right
2	now, so that's really the question.
3	MR. KATZ: Thank you, that's a
4	helpful clarification.
5	MR. ROLFES: I suspect, you know,
6	without looking at the specific cases I
7	suspect that you know I do see from Ron's
8	review of these cases that a hypothetical 12
9	or 28 radionuclide was not used in these
10	cases. We did assign thorium intakes but we
11	did not assign recycled uranium intakes in
12	four of the five cases. You know, I'd have to
13	take a look back at the specifics of that dose
14	reconstruction because if we did a best
15	estimate of an individual's uranium intake and
16	the internal dose from uranium and then add in
17	the recycled uranium contaminants that would
18	be more of an issue than if we basically
19	overestimated the individual's uranium intake
20	and you know, used another bounding approach,
21	an overestimating approach, early on. You

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

77

1	know, there could be some other approach that
2	we'd used so I have to take a look back and
3	we'll do what we can to provide a date after
4	this Work Group meeting with the response.
5	It's probably not going to be till June before
6	I can respond so.
7	DR. BUCHANAN: Okay. Our third
8	item on the - our action - SC&A's action item
9	list was the neutrons at Weldon Spring. And
10	at the last meeting I brought up the fact that
11	the neutron N/P value was obtained at
12	different times, the neutrons obtained in '95,
13	the gamma was obtained in 2001. And Stu asked
14	me to send that information to him and I did,
15	I sent that out to the Work Group and to Stu
16	and NIOSH on the second of February. This was
17	quoted from the Fernald TBD. And so that was
18	one issue we wanted NIOSH to respond to was
19	while the numbers came out, the N/P ratios are
20	reasonable, the technical method of
21	determining them did not look solid.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

(202) 234-4433 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

78

1	Issue number four was - or item
2	number four I should say -
3	MR. FITZGERALD: Do you want to -
4	CHAIRMAN GIBSON: Does DCAS have
5	some response on issue 3? I mean that's.
б	MR. ROLFES: Well, we did look
7	back. This has been discussed quite a bit for
8	Fernald and the information that was presented
9	to us by SC&A identified, you know, that - I
10	don't know if you wanted to summarize your
11	data here, but it basically pointed out that
12	the neutron dose rate was taken in 1995 and
13	the photon dose rates were conducted in 2001.
14	It was in a green salt storage area. We
15	discussed this quite a bit and it came to a
16	resolution in the Fernald Working Group that
17	this wasn't an issue. We're using the 95th
18	percentile neutron-to-photon ratio of 0.23 to
19	1 from Fernald measurements to assign
20	unmonitored neutron doses for Fernald workers
21	that were in areas where they handled enriched

NEAL R. GROSS

79

1	uranium. And it was primarily like the green
2	salt storage areas. Really, since we're using
3	the 95th percentile value there's no
4	indication of, you know, it being in excess of
5	that at the Weldon Spring Plant. And that's
6	especially considering that the types and
7	quantities of materials at the Weldon Spring
8	Plant as well as the enrichments of the
9	materials at the Weldon Spring Plant were
10	lower than those materials that were handled
11	at the Fernald site. So we really don't see
12	any kind of reasonable scenario where we could
13	have gotten a higher neutron-to-photon ratio
14	or a higher neutron dose rate at the Weldon
15	Spring Plant.

16 DR. MAURO: Mark, this is John. Ι have to apologize, you know, I don't recall 17 the details of that. I do recall at one point 18 we did some MCNP modeling of alpha Ns for I 19 20 think it was green salt that might have been 21 in storage that was enriched and you folks had

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

80

1	an approach for deriving the neutron dose from
2	that. I don't recall neutron-to-photon ratios
3	having some play there. It may have. So I
4	hear what you're saying but I have to say it
5	doesn't, you know, I'm drawing a complete
б	blank on how that issue was resolved. I do
7	not remember it being resolved from a neutron-
8	to-photon perspective. I remember it being an
9	MCNP run on alpha N. But I think maybe we owe
10	John Stiver, maybe we could take a look at
11	what the history of that issue was and how it
12	was resolved and so we have a better
13	understanding of the context and how it was
14	resolved and whether it is in fact applicable
15	to Weldon. It sounds like, Mark, you're
16	drawing upon some experience we had a few
17	years back on Fernald and I apologize, I just
18	don't recall.
19	MR. STIVER: John, I just stepped

20 out for a second and missed that little 21 exchange. Could you -

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

81

1	DR. MAURO: The idea, the bottom
2	line is they were discussing doing neutron
3	dose calculations and using a neutron-to-
4	photon ratio strategy that was originally
5	developed, applied and accepted at Fernald and
6	that the situation at Weldon is identical and
7	therefore should solve the problem. There are
8	some concerns that were brought up by Ron
9	regarding the methodology used to get to the
10	ratio, the neutron-to-photon ratio. It
11	sounded like Ron wasn't all that disturbed by
12	the ratio itself, but the methodology that -
13	by which they got to that ratio.
14	MR. STIVER: The basis for the
15	ratio.
16	DR. MAURO: Yes. And then of
17	course reference was being made that we went
18	through this process already for Fernald. And
19	I have to say this must go back several years.
20	I don't recall it and perhaps it would be
21	appropriate for us to sort of refresh our

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

(202) 234-4433

1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

82

1	memory on what the process was, you know, how
2	we came about whatever we came about regarding
3	the resolution of neutron issues because there
4	are no neutron issues on the table at Fernald
5	right now.
6	MR. STIVER: That seems
7	reasonable, yes.
8	DR. MAURO: Right. Let us do a
9	little homework, it won't take very much time,
10	and feed back. And then I think maybe Ron and
11	John, you could work out the degree to which
12	the issue was in fact appropriately resolved
13	on Fernald and the degree to which it applies
14	to Weldon.
15	MR. STIVER: Okay, will do.
16	MR. ROLFES: This is Mark Rolfes.
17	And to give you a little bit of background,
18	what we had discussed at Fernald, SC&A had
19	reviewed our approach and had tried to come up
20	with an approach that would result in a higher
21	neutron-to-photon ratio, or a higher neutron

NEAL R. GROSS

(202) 234-4433

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

83

1	dose rate. And our comment on the approach
2	that was taken was that you had produced 2
3	percent enriched green salt array that was not
4	in a safe storage configuration so there was
5	neutron multiplication going on. And so I
6	think SC&A withdrew their review at that time.
7	DR. MAURO: Yes, see I do remember
8	that. I remember when we ran - we ran a
9	calculation where we were trying to do a
10	bounding and our bounding was such that we'd
11	have a criticality situation and it couldn't
12	occur. But I didn't remember it within the
13	context of a neutron-to-photon ratio. I
14	remembered it more within a context of running
15	an alpha N calculation for a pile, some
16	conical pile and you were right. I remember
17	we made the error that assumed a certain size
18	pile that would have been a critical mass and
19	of course that could not have occurred. But I
20	don't remember it within the context of
21	neutron/photon ratios. And it won't take us

NEAL R. GROSS

84

1	long to get up to speed and clarify.
2	MR. FITZGERALD: Let me offer an
3	alternative. I defer to the Work Group but
4	maybe NIOSH could just simply for the purposes
5	of this Work Group since this Work Group in
6	toto hasn't been involved with the Fernald
7	discussions so we're completely ignorant of
8	all this history. If Mark, you can simply,
9	you know, lay it on the table as you did at
10	Fernald for this Work Group and John and John
11	and Ron and Joe and Work Group can together
12	understand how that would be applied in this
13	context. Because I think you said something
14	important which I wasn't fully aware of, the
15	you know, the enrichment levels that are lower
16	at Weldon so there's a degree of conservatism
17	that would be factored in in applying that
18	approach to Weldon. And that would be useful
19	just to lay that out as well. And then all of
20	us can take a look and sort of judge in this
21	Work Group whether it makes sense.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

85

1	MR. ROLFES: I actually sent an
2	email to Ron awhile back with the excerpt from
3	the Fernald Working Group where this issue was
4	discussed and I think I also provided some
5	additional information. I - unfortunately I
6	can't get into my email right now, I'm sort of
7	blocked out here for some reason. I was
8	trying to find the date of the email that I
9	had sent out.
10	MR. FITZGERALD: It sounds like it
11	was some kind of analysis or something beyond
12	the discussion.
13	MR. ROLFES: Well, from us, from
14	our standpoint. I don't know if we have
15	addressed this in the Evaluation Report as
16	well, but let me flip through here. Maybe
17	someone on the phone, maybe Monica or Bob or
18	anyone out there, could you point out anywhere
19	in our Evaluation Report where we might have
20	addressed neutron exposures?
21	MR. FITZGERALD: I guess what I

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

86

1	was looking for is this - sort of cribbing off
2	the Fernald discussion maybe just providing a
3	brief analysis that can reference Fernald but,
4	you know, for the situation at Weldon. It
5	would at least provide a basis for the Work
6	Group to come to closure on it.
7	DR. CHEW: Mark, this is Mel.
8	It's on page 60 of 92 on the ER.
9	MR. ROLFES: Okay. Let's see
10	here.
11	CHAIRMAN GIBSON: And rather than
12	go through something that we don't have in
13	front of us, you know, I think from what Joe's
14	saying, and not only this issue. I think it's
15	important that any issue for this Work Group
16	that applies as any Work Group that SC&A and
17	DCAS has worked on, that final product needs
18	to be brought before this Work Group so that
19	we can look at it on the agenda and see that
20	we agree, and secondly so that it's - it's on
21	the transcript, it's on the record for the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

87

1	claimants. You know, this - we've had quite a
2	long time between meetings, we've had a list
3	of action items and it's - well, this was
4	discussed and resolved because of Fernald and
5	we go on to something else. And I just, I
б	don't think that's - that's not fair to the
7	Work Group, it's not fair to the claimants. I
8	think we need to be a little more detailed in
9	making sure that everything is clear on the
10	record, especially for the claimants.

11 MR. ROLFES: Okay, thanks Mike. 12 I'll read our little section here. This is 13 actually on - from SEC Evaluation Report 143 dated March 23, 2010. 14 It's on page 32 of 90 15 of my copy here. It's section 5.2.2.3. It 16 says, "The Weldon Spring Plant was operated as an integrated facility for the conversion of 17 uranium ore concentrate from small quantities 18 of recycled scraps of pure uranium trioxide, 19 20 uranium tetrafluoride and uranium metal. During these processes and during the storage 21

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

88

1	of uranium tetrafluoride neutrons were not
2	anticipated at the Weldon Spring Plant. Any
3	neutrons would have resulted from the alpha
4	neutron reaction from uranium tetrafluoride,
5	green salt, or processing the slightly
6	enriched uranium which was 1 percent or less
7	U-235.

Weldon Spring operational 8 "Most employees were involved with the processing of 9 natural and depleted uranium and were assigned 10 11 to reqular beta gamma dosimeter badge However, in a special study of the 12 monitors. 13 feed materials production center, neutron 14 made in and around the measurements were drums stored uranium 15 arrays of and 16 tetrafluoride up to 2 percent enrichment to determine the potential for neutron exposures. 17 study included of Landauer 18 The the use NEUTRAK ER dosimeters as area badges over the 19 20 period of one quarter and a special survey using a Nuclear Research Corporation model NP2 21

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

89

1	portable neutron meter. The results of the
2	study indicate neutron exposures were minimal,
3	a maximum of 0.089 millirem per hour for the
4	area badges and less than the minimum
5	detectable level of 0.02 millirem per hour for
6	the portable neutron monitor. Calculations
7	performed for Battelle TBD-6001 on similar
8	materials are in agreement with the Fernald
9	measurement data and support the conclusion
10	that neutron dosimetry is not needed when
11	processing uranium tetrafluoride under these
12	parameters because there's no significant
13	potential for neutron exposures."
14	It goes on to say in the next

14 goes on to say in the next Τt 15 paragraph that, "Even though the Weldon Spring 16 Plant received enriched uranium it was always less than 1 percent enriched. Therefore, the 17 potential for neutron exposure was very low. 18 The slightly enriched uranium was processed in 19 buildings 103, 105, 201 and 301, and those 20 employees that processed the slightly enriched 21

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

90

special 1 assigned uranium were neutron 2 dosimeter badges to be worn in connection with 3 the regular film badge dosimeters. Neutron dose results for these Weldon Spring employees 4 have not been located, probably because there 5 was no measured neutron doses." 6 So that's 7 what we've discussed in our Evaluation Report and that was providing our basis for the use 8 9 of Fernald data to assign neutron doses to 10 workers who were not monitored at the Weldon Spring Plant. 11

MR. FITZGERALD: Ron, do you want to elaborate on some of this? I think you had some questions on the technical basis.

DR. BUCHANAN: I really don't have 15 16 a problem with your statement. Just from a scientific 17 point of view when you do 18 neutron/photon ratio you try to do the same experimental setup as similar as you can to 19 20 measure, and usually you do it simultaneously your neutron/photon doses 21 and then measure

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

91

1	determine the N/P value. What I have a
2	problem with is that - is that this was
3	measured in 1995 on canisters for the neutron.
4	Six years later the gamma was measured in
5	2001 on drums. Just from a technical point of
6	view that is not a sound way to measure N/P
7	values. That was my main concern and that's
8	the reason I brought the issue up and
9	forwarded that information to NIOSH from the
10	last meeting. I really don't have a problem
11	otherwise, it's just that technically it's not
12	a sound way to determine N/P values.
13	MR. ROLFES: To make a difference
14	though, in defense of what we have here, you
15	know some major changes would have to take
16	place. For example, the enrichments that were
17	handled or the quantities of material that
18	were handled at the Weldon Spring Plant and we
19	have no indications that the materials that
20	were handled at the Weldon Spring Plant ever
21	exceeded the material quantities and storage

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

92

1	configurations and enrichments that were
2	handled at Fernald. So you know, certainly I
3	agree with you, you try to keep, you know, as
4	many variables as - try to keep as few
5	variables as possible in any kind of
б	scientific measurements but then again, you
7	know, in looking at what was done we would
8	have to have some question, you know. There
9	would have to be a significant change in a
10	source-term to drastically affect the neutron
11	dose rates or the N/P ratio resulting from
12	them.
13	DR. BUCHANAN: And I don't argue
14	with that. I'm not arguing using Fernald data
15	for Weldon Spring. My concern is just from a
16	technical point of view that the measurements
17	done, the way the N/P values were determined
1.0	

DR. MAURO: Ron, where you refer to the N/P values as they were determined and described we just heard or read to us, is that

is not scientifically valid.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

18

93

1	the measurements that were made at Fernald or
2	are those the measurements that were made at
3	Weldon?
4	DR. BUCHANAN: At Fernald.
5	DR. MAURO: Okay.
6	DR. BUCHANAN: This is directly
7	out of the Fernald TBD page 18 and 19.
8	DR. MAURO: Okay. We at SC&A
9	certainly need to go back and take a look at
10	that to see, you know, clearly we have
11	resolved that issue and I'll be the first to
12	say well, maybe there are some questions
13	regarding it. Hate to do that, but we'll take
14	a look at it and let you know what we find.
15	And then of course we could all make a
16	judgment as to whether or not everything's
17	okay or not, not only for Weldon but also for
18	Fernald.
19	MR. KATZ: Is that your point,
20	Ron?
21	DR. BUCHANAN: My point is -

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

94

1	MR. KATZ: I mean you're saying
2	technically it's not correct, but I'm just
3	trying to understand what you're saying you
4	would like to see to resolve it.
5	DR. BUCHANAN: Well, I'm just
6	bringing up the fact that if you're doing N/P
7	values and you go in the lab and you measure
8	them, this is not the way you do it, that you
9	don't do it six years later. You don't do the
10	neutron one time and six years later do the
11	gamma under a different geometry. You would
12	go and set up a lab and you would do the
13	measurements simultaneously if you're going to
14	use those values to assign dose to someone.
15	You don't do it six years later using drums in
16	one case and canisters in another case.
17	CHAIRMAN GIBSON: And so
18	just to clarify for me, this is really non-
19	scientific. Maybe you've already explained
20	this. Why was that done? At one time one
21	measurement and six years later the other

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

95

1	measurement.
2	MR. ROLFES: Is that question for
3	me?
4	CHAIRMAN GIBSON: Yes.
5	MR. ROLFES: I'll have to take a
6	look back but basically they were - at the
7	Fernald site they were actually looking with
8	different methodologies to try to detect
9	neutron dose. Because the dose rate was so
10	low they weren't able to detect it with
11	typical detection equipment. They had
12	actually put in a few different types of
13	materials and CR-39 trackage materials as well
14	as some bubble dosimeters I think. So I'm not
15	sure, I'd have to take a look back at the
16	data. I don't know if anybody on the line
17	might be able to help me out with that, but
18	they measured neutron dose rates at Fernald
19	based upon the sensitive, let's see here.
20	DR. BUCHANAN: Bubble detectors I
01	heliowe

21 believe.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

96

1	MR. ROLFES: Yes, it was the
2	bubble detectors I believe. And let's see
3	here. So we've got a neutron dose rate and
4	that neutron dose rate wouldn't differ unless
5	you increased the enrichments or increased the
6	amount of material that would increase the
7	alpha neutron interactions that were primarily
8	responsible for that neutron dose rate. We
9	have no indication that that was done at
10	Fernald and certainly not at Weldon Spring.
11	So you can say that that 0.089 millirem per
12	hour would be a bounding value for neutron
13	dose rates. Now, you'd have to compare that
14	to the gamma dose rate to get your N/P ratio.
15	And we have a neutron dose rate so it's not,
16	you know, we don't - I'm trying to think. I
17	don't know, is there anyone on the line, maybe
18	Monica or Bob possibly or Mel that might be
19	able to elaborate a little bit on the neutron
20	dose measurements and, you know, any reasoning
21	why the - or explanation for why the time

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

97

1	period wasn't the same?
2	CHAIRMAN GIBSON: Or why didn't
3	they take the photon readings in '95 as well.
4	MR. ROLFES: Right, right.
5	DR. CHEW: Mark, this is Mel. I'm
6	looking at the distribution again. I think we
7	don't really need to have the photon
8	measurements or calculation because we do have
9	direct readings from the portable neutron
10	meters, as you said, of 0.089 millirem per
11	hour, and that's what we should be using. So
12	I don't think we need to even use that N/P
13	ratio at all.
14	CHAIRMAN GIBSON: Okay, that's
15	another approach as well. I mean, if we've
16	got a bounding value of 0.089 at Fernald based
17	upon the materials that were stored there
18	versus the Weldon Spring Plant, the Weldon
19	Spring Plant handled lower enrichments and
20	lower quantities of the same chemical form of
21	uranium. So that bounding value of 0.089 from

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

98

1	the	Fernal	d si	te shoul	d ce	ertair	nly enca	psulate
2	or	bound	any	values	at	the	Weldon	Spring
3	Pla	nt.						

4 DR. BUCHANAN: Yes, this is Ron, 5 SC&A. That's true if the geometry, the mix 6 and everything is the Τf same. your 7 container's the same, you've got the same of attenuation, 8 amount you've got the same 9 of liquid and solid concentration. amount 10 Your neutron emissions and attenuation within the source itself is going to vary depending 11 on the geometry of the container and so your 12 13 neutron, if you're going to use direct neutron then 14 measurements your geometry, your container and everything has to be similar at 15 16 both sites. If you're going to use N/P ratio 17 then it isn't quite as crucial. But if you measure neutrons on a barrel filled with water 18 and you measure gamma on something else, a 19 20 drum filled with solids you're not getting the attenuation of the neutrons 21 same or gammas

NEAL R. GROSS

99

1	that	you	're	goiı	ng	to	see	if	they	're	mixed	and
2	meası	ıred	at	the	sa	me	time	•				

3 Just coming into MR. FITZGERALD: this a little more fresh than a lot of folks 4 5 on the phone, it seems to me that it's not even the application part. 6 It sounds like 7 once you have these basic values whether it's the N/P route or just neutron measurements, 8 beyond that I don't know if there's as much of 9 an argument given the enrichment issues you've 10 11 talked about. But that source, that source calculation seems to be a little bit fuzzy 12 13 right now. There's a couple different options 14 that you might want to look at. It sounds like maybe that would be useful for the Work 15 16 Group to get your, you know, get your 17 thinking, whether it's a new thinking or maybe the old thinking once you look at it and have 18 that presented back and then we could react to 19 20 it. But it's not so much - it does sound like there's an issue relative to applying it to 21

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

100

1	Weldon once you do come up with that value.
2	It sort of goes back to Fernald as, you know,
3	what that value means and where it came from
4	and whether it's the basis for that value that
5	seems to be in question right now.
6	MR. ROLFES: I'm looking back from
7	the, let's see, from ORAU-TKBS-0017-6.
8	MR. FITZGERALD: What site?
9	MR. ROLFES: This is the Fernald
10	site and it's discussing the development of
11	the neutron-to-photon ratios. I'm just
12	looking here. What we have - one of the
13	explanations - or explanations for the
14	difference in the measurements, couldn't store
15	2 percent enriched green salt in a drum so it
16	was stored in a smaller canister. So you've
17	got, let's see, we've got some data in there,
18	table 6-9, measured neutron dose rates at
19	Fernald for different types of material.
20	We've got average measured neutron dose rates
21	for depleted and low-enriched uranium which

NEAL R. GROSS

101

1	range from 1.25 percent to 2 percent. So that
2	was compared to the photon doses measured on a
3	large array of drums. And so that's primarily
4	what I suspect one of the bases or one of the
5	reasons for the differences in how the
6	measurements were made because we couldn't
7	store 2 percent enriched uranium in a drum
8	because of safe storage requirements.
9	Enriched uranium was stored in a smaller
10	canister.
11	DR. BUCHANAN: And it would have
12	
	been great if they had just put a gamma survey
13	meter there with the neutron meter and got a
13	meter there with the neutron meter and got a
13 14	meter there with the neutron meter and got a point. And you know, and then I wouldn't have
13 14 15	meter there with the neutron meter and got a point. And you know, and then I wouldn't have a problem.
13 14 15 16	meter there with the neutron meter and got a point. And you know, and then I wouldn't have a problem. MR. ROLFES: Sure, sure.
13 14 15 16 17 18	<pre>meter there with the neutron meter and got a point. And you know, and then I wouldn't have a problem. MR. ROLFES: Sure, sure. DR. CHEW: This is Mel. Can I</pre>

21 production from the alpha N reaction. We all

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

102

1	know	, we	kno	ow th	le cro	oss-	-secti	ons	are	very,
2	very	low	for	this	kind	of	react	ion.	You	want
3	to	confi	irm	that	wit	h	your	own	int	ernal
4	calcu	ılati	on?							

5 DR. MAURO: Yes, we actually - I recall when we were looking at this issue. 6 We 7 modeled the - and it may have been to see if the neutron/photon ratio sort of rang true. 8 9 We modeled the alpha Ν usinq 2 percent enriched uranium which is sort of the upper 10 bound number that has been used for Fernald as 11 being a reasonable value. And I remember it 12 being a conical pile actually stored outside 13 14 and not in a drum. And we ran it, and so we with numbers. Whether it 15 came up was 16 expressed in terms of a neutron dose rate or 17 it was expressed in terms of a neutron/photon ratio 18 that later shown to be on was inappropriate because the cone, the conical 19 20 pile we assumed would have created a critical 21 So we withdrew that analysis as being mass.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

103

1	erroneous. Now, how the issue eventually was
2	resolved and you know, and accepted is
3	something that I don't recall and is probably
4	worth us going back and taking a look at it.
5	And then of course between us and John, myself
6	and Ron we can just take a look and say okay,
7	you know, was the issue resolved appropriately
8	on Fernald and if so, does it have direct
9	applicability to Weldon. So I mean, that
10	seems to be the way to get - to bring this
11	thing to closure pretty quickly.
12	DR. CHEW: Okay. I think you need
13	to realistically model what the real piles
14	need to be because I think Stu Hinnefeld was
15	there when he mentioned that the pile that you
16	did model would have gone critical.

Right, 17 DR. MAURO: oh Ι yes, remember 18 that and you know, we were embarrassed. 19

20 DR. CHEW: No, don't worry.
21 DR. MAURO: And it's not difficult

104

1	for us to go back and redo that. Those kinds
2	of things are done quickly.
3	DR. CHEW: Okay. And I think you
4	need to look at the total neutrons produced,
5	neutrons per second, and then you can do any
6	geometry you want to to get the dose rate.
7	Okay?
8	DR. MAURO: Oh yes. We actually
9	get the fluxes, energy flux coming off, you
10	know, as a function of distance. Yes, we'll
11	take a look at it and get back. We'll
12	basically be talking to Bob Anigstein and
13	looking back at the history of this thing. It
14	shouldn't be difficult sort of to reconstruct
15	the history of how this issue was resolved.
16	DR. CHEW: Make sure you keep on
17	building this model so it looks like a
18	reactor.
19	DR. MAURO: Yes.
20	DR. CHEW: Okay, thanks John.
21	DR. MAURO: Okay.

105

1	MR. KATZ: Okay, so this has ping-
2	ponged back and forth a little bit as to who
3	has an action item. John is suggesting that
4	SC&A do the homework of reconstructing -
5	MR. FITZGERALD: Workers -
6	DR. MAURO: Ted, the only reason I
7	bring it up is that, you know, the very fact
8	that I'm sitting here, we're talking about
9	Fernald and I don't remember how that issue
10	was resolved, but it certainly was resolved
11	and I think we owe it to not only the Weldon
12	group but also the Fernald group to be clear
13	on how we did it. Because it's possible that
14	we resolved the issue but maybe there still
15	are some matters of the type that Ron is
16	describing that we need to take a look at. I
17	hate to reopen an issue, but I feel that given
18	the way this is unfolding we do need to take a
19	look at it, you know, and make sure that we
20	close that issue appropriately.
21	MR. KATZ: I don't have a problem

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

106

1	with that if that's -
2	CHAIRMAN GIBSON: Well, I want to
3	say this, is I want it brought back to this
4	Work Group how it was resolved at Fernald and
5	then I also want a final discussion on this
6	issue 3 that SC&A raised explaining in layman
7	terms why the neutron doses were taken in '95
8	and why the photon readings were taken in
9	2001. Would there have been a difference if
10	they had taken them both in '95? Would there
11	have been a difference if they had taken them
12	both in 2001? And just so that the Work Group
13	can feel that it's satisfied with the issue
14	and also so it makes a little more sense to
15	the claimants.
16	MEMBER LEMEN: And what time frame
17	are you talking about?
18	MR. KATZ: For reporting back?
19	CHAIRMAN GIBSON: As soon as
20	possible. You know, we - you know, I know
21	everyone's busy and I'm not trying to bust

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

107

1	anyone's chops but it's been some time since
2	we had a meeting. We had a meeting scheduled.
3	It was canceled because there was no progress
4	and it seems to me that this meeting is
5	becoming, well, there's issues on the table,
6	it's been resolved and we try to move on and
7	I'm just not satisfied with that. I think
8	there needs to be a little more detail on the
9	table so that this Work Group can try to say
10	we agree with some of these issues and they're
11	closed or we have some specific questions that
12	we want you guys to go back and look at.
13	DR. MAURO: Mike, this is John.
14	We're going to jump on this immediately and
15	I'm going to have an answer on how this issue
16	was closed and whether there are problems or
17	not on Fernald by next week. Because I do not
18	want any matters like this sort of hanging out
19	at the time of the St. Louis meeting. So
20	we're going to close the door and understand
21	exactly where we are by next week on this

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

108

1	matter for Fernald.
2	CHAIRMAN GIBSON: Well, and I
3	understand that we have a meeting coming up in
4	St. Louis but I don't want to have a few
5	convenient if you will answers for the people
б	in St. Louis. I want this Work Group to make
7	some substantive progress regardless of
8	whether we have a meeting in St. Louis, you
9	know. I want to see some things get done. I
10	just think we're getting behind on it.
11	MR. KATZ: Right, okay. But John
12	says he'll close the book on this one or he'll
13	try to close the book on this one before St.
14	Louis which is certainly before another Work
15	Group meeting.
16	DR. MAURO: Sure, absolutely.
17	MR. FITZGERALD: And John, the
18	second part, I'm sort of intrigued by Mel's
19	comment. I mean, if in fact because of the
20	temporal and the source-term differences there
21	may be some fault with using the N/P ratio,

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

109

1	could you in fact use the neutron readings
2	directly or not. I mean, it might as well I
3	think answer those kind of questions as well
4	so the Work Group gets the full picture.
5	DR. BUCHANAN: Yes, would there be
6	strict limitations if you used a neutron dose
7	directly, would restricted limitations on
8	where that would apply or would it be sort of
9	a general, that the geometry wouldn't make a
10	lot of difference? You know, we have to know
11	how versatile using the neutron dose would be
12	directly.
13	CHAIRMAN GIBSON: And Dick, was
14	your question just on this one issue or was it
15	in general? Did you get your question
16	answered?
17	MEMBER LEMEN: No, I think you
18	answered it.
19	CHAIRMAN GIBSON: Okay.
20	MEMBER LEMEN: And John answered
21	it.

110

1	CHAIRMAN GIBSON: Okay.
2	DR. BUCHANAN: Is NIOSH going to
3	provide anything on the neutron or are they
4	going to wait on that? What's your decision
5	there?
6	MEMBER LEMEN: You mean the issue
7	of the gap in time?
8	DR. BUCHANAN: Right. I imagine
9	it was when data was available. I mean that's
10	probably the answer. If they didn't just
11	happen - they didn't use gamma measurements in
12	'05 so NIOSH found the data in '01 - I mean
13	'95 and they found data in '01 and applied it
14	back to '95. That's probably the answer, that
15	the data wasn't there.
16	MEMBER LEMEN: Well, that
17	shouldn't be hard to find out then. I mean,
18	you should be able to get that in the very
19	near future. Right? NIOSH?
20	MR. ROLFES: Sure. Let's see.
21	I've been searching for the transcripts where

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

111

1	this was discussed at Fernald and the
2	transcripts of the discussion on neutron doses
3	at Fernald came from our Work Group meeting on
4	October 28th, 2008. It was pages 365 to 367.
5	DR. MAURO: Give that to me again?
6	I'm writing it down and catching up to you.
7	October 28th?
8	MR. ROLFES: October 28th, 2008
9	and it was pages 365 through 367.
10	DR. MAURO: Thank you very much.
11	MR. KATZ: So I think we could
12	just assume DCAS will come prepared to discuss
13	this at the time we discuss it at the next
14	Work Group meeting.
15	CHAIRMAN GIBSON: Sounds good. Is
16	there anything else going to be discussed on
17	SC&A's issue 3 or did we about close that out?
18	DR. BUCHANAN: On the neutron
19	issue, no. None.
20	CHAIRMAN GIBSON: So before we go
21	on to 4 you want to take about a 10-minute

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

112

1	break?
2	MR. KATZ: Okay, 10 minutes and
3	I'm going to put the phone on mute.
4	(Whereupon, the above-entitled
5	matter went off the record at 10:47 a.m. and
б	resumed at 11:04 a.m.)
7	MR. KATZ: Okay, this is Ted Katz.
8	Welcome back. It's the Weldon Spring Work
9	Group, the Advisory Board on Radiation Worker
10	Health. We're just returning from a short
11	comfort break. Ron?
12	DR. BUCHANAN: Okay. Ron
13	Buchanan, SC&A again. Just to get everybody
14	on the same page here we're on item number 2
15	of the agenda. I'm going through our action
16	items and we - I covered item number 1, 2 and
17	3. We're looking at item number 4 which is
18	enriched uranium question. We brought up the
19	fact that perhaps Weldon Spring received
20	greater than 1 percent enriched uranium. And
21	last time NIOSH was to send us two references

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

113

1	which was to illustrate that it was less than
2	1 percent. And so I looked at those
3	references that they sent from the Site
4	Research Database and both references coded
5	handling procedures to handle something like
6	0.86 percent and 0.90 percent enriched
7	uranium. I agree that those were both less
8	than 1 percent. However, they were handling
9	procedure SOPs, not necessarily any
10	documentation that the site handled less than
11	1 percent enriched uranium.
12	That was the four items we had on
13	our action item list. Now two other items
14	that we did participate in. Do you want that?
15	MR. FITZGERALD: Did we resolve
16	that?
17	DR. BUCHANAN: I didn't know if we
18	wanted to talk about it when they responded or
18 19	wanted to talk about it when they responded or do you want to talk about it now?

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

114

1	DR. BUCHANAN: Okay.
2	MR. ROLFES: I was just going to
3	say, you know, the site didn't typically
4	document what they didn't have, they only
5	documented what they did process or what they
6	did have. So we found no indication that they
7	had greater than 1 percent enriched uranium in
8	our reviews of the records for, you know, the
9	Weldon Spring site as well as any other
10	documents tied to them possibly, like for
11	example you know any shipments from Fernald
12	for example. So we have no indication that
13	greater than 1 percent enriched uranium was at
14	the Weldon Spring Plant.
15	MR. FITZGERALD: Which I think is
16	a more definitive answer. I think the SOP
17	sort of talked about what you would do rather
18	than whether or not there was anything. What
19	you're saying is that you haven't seen
20	anything -
21	MR. ROLFES: Correct.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

115

1 MR. FITZGERALD: - to give you 2 pause. 3 And no interviews MEMBER LEMEN: have indicated otherwise. 4 5 ROLFES: Mel. I MR. Let's see. 6 know you were responsible for conducting a few 7 of the interviews with Weldon Spring Plant Do you recall if there was a 8 former workers. 9 discussion of the enrichments that were 10 handled at the Weldon Spring Plant in any of those interviews? 11 I think we asked the 12 DR. CHEW: 13 question to the interviews and I just don't 14 recall right now. I think pretty much we had confirmed that yes, there was low enrichment. 15 16 I don't remember exactly the number, but so that's how much I recall. 17 But I think the 1 percent was generally discussed. 18 Mark, this is Robert 19 MR. MORRIS: If you give us a few minutes we can 20 Morris. go back and review while you're continuing the 21

(202) 234-4433

116

1	conversation and see what we've got.
2	MR. ROLFES: Okay. I think in our
3	Evaluation Report one other thing we had
4	identified as well, that 99 percent of the
5	throughput for the Weldon Spring site was
6	natural and/or depleted uranium. So you know,
7	the 1 percent would have been of materials
8	other than natural or depleted uranium would
9	have been either thorium or the slightly
10	enriched uranium. So based on everything I've
11	seen the slightly enriched uranium that was at
12	the Weldon Spring Plant was less than 1
13	percent enriched in U-235.
14	MR. RICH: Mark, this is Bryce.
15	MR. ROLFES: Yes, Bryce.
16	MR. RICH: The Ohio Field Report
17	on Appendix B-4 has a documentation of the
18	enriched and normal and depleted uranium. So
19	it is documented there.
20	DR. BUCHANAN: Is that on the
21	Research Database?

117

1	MR. RICH: Yes.
2	DR. BUCHANAN: And can you give me
3	that number?
4	MR. RICH: Yes, hold on.
5	MR. ROLFES: Was this Appendix B
б	of the DOE 2000?
7	MR. RICH: SRDB 3644.
8	DR. BUCHANAN: Thirty-six forty-
9	four. And do you have a PDF page number that
10	that's on?
11	MR. RICH: It's Appendix B-4.
12	DR. BUCHANAN: Appendix B-4.
13	Okay. I think that the last time I tried to
14	look - is that on the Site Research Database
15	now? Last time I tried to pull up 3466 it
16	wasn't available.
17	MR. ROLFES: Thirty-six forty-
18	four.
19	DR. BUCHANAN: Thirty-six forty-
20	four.
21	MR. ROLFES: And you know,

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

118

1	actually Stu had asked me about that reference
2	the other day and I had a problem accessing
3	it. It is available, we can make a copy
4	available to SC&A on the K: drive. So -
5	MR. RICH: I have it on my
6	database and it is in reference to 3644 I
7	think, although I haven't tried pulling it up
8	within the last week or so.
9	MR. STIVER: Well, this is John
10	Stiver. I have a copy I can provide to you.
11	DR. BUCHANAN: Because I tried to
12	pull that up about a month or two ago and it
13	wasn't available.
14	MR. ROLFES: I had the same
15	problem.
16	MS. HARRISON-MAPLES: I just
17	pulled it up. It is available now.
18	DR. BUCHANAN: Okay, thank you.
19	MS. HARRISON-MAPLES: You're
20	welcome.
21	MR. RICH: It's on page 15 of the

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

119

1	enriched uranium on B-4.
2	DR. BUCHANAN: Okay, thank you
3	very much, that'll be helpful.
4	DR. CHEW: Hey Ron? This is Mel.
5	Can you hear me?
6	MR. KATZ: Yes, Mel.
7	DR. CHEW: This is a briefing with
8	John. John, I'm sorry I had to leave but -
9	right before you went on break here. When you
10	guys start modeling the neutrons make sure
11	that - I don't need to tell you that the -
12	MR. KATZ: Can you stop one
13	second? I think you may have a speaker phone
14	or something. Someone has a speaker phone or
15	something because we're getting sort of
16	reverb, an echo of everyone speaking. It just
17	stopped so maybe you're good now, Mel.
18	DR. CHEW: I hear a child
19	actually. Hey John, I think just to make sure
20	that when you folks model this thing you're
21	going to model for 2 percent and 1 percent so

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

(202) 234-4433

1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

120

1	it would be relevant to Fernald and Weldon
2	Spring. And we'll be very interested in
3	looking at the - what you're going to be using
4	for assumptions for modeling. And especially
5	as you start building this pile as you well
б	know there will be attenuation in moderation
7	and using the right cross-section. I don't
8	need to tell you.
9	MR. FITZGERALD: Flipping back to
10	the previous issue. On this issue I guess it
11	sounds like the action is with us to go
12	validate what is in those report - that
13	report.
14	DR. BUCHANAN: That report and see
15	if it does document that.
16	MR. FITZGERALD: Document the
17	historic source-term. I think that will
18	address the issue.
19	DR. BUCHANAN: We have no issue
20	really. We can handle 1 percent and our
21	question was is there any documentation that

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

121

1	they didn't handle over 1 percent.
2	MR. KATZ: Hold on a second.
3	Someone has their line open and we're getting
4	an echo. So if everyone on the line who, when
5	you're not addressing would you please mute
б	your phones, *6 if you don't have a mute
7	button. Thanks.
8	MR. FITZGERALD: And we can take
9	that action in realtime so I mean, it's just a
10	matter of looking.
11	DR. BUCHANAN: Yes and if we look
12	at that and it looks like that it does
13	document that Weldon Spring did not receive
14	over 1 percent enrichment then we can close
15	the issue. But at this time we'll leave it
16	open until we do document that.
17	Okay, so that was item, action
18	item 1 through 4 for SC&A. Now, two other
19	events have occurred I just want to summarize
20	and I turn it over to NIOSH. Mark asked that
21	I send him some accident case numbers and I

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

(202) 234-4433

1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

122

1	did	that	-

2 MR. KATZ: I'm sorry. We're just, 3 we're getting this echo. Someone doesn't have their phone muted on the line. 4 If you don't 5 have a mute button please use *6. It's -6 we're still hearing it. Someone on the line, someone has the line open and they don't have 7 their phone muted. Please use *6, mute your 8 9 Maybe you have - right. phone. Maybe you 10 have a speaker phone on instead of using the 11 handheld. Maybe that's the problem. Okay, I'm just going to turn down the volume so we 12 13 don't hear it so much. Okay, qo ahead. 14 Sorry, Ron.

Okay. And so I did 15 DR. BUCHANAN: 16 send those three accident cases to Mark to 17 analyze for accidents in the incident 18 question. And the last item is that SC&A received NIOSH's reply to some of the issues 19 20 on - a couple of weeks ago on April the 21st and we read over some of those. 21 Some of the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

123

1	simpler ones we were able to address or
2	discuss when Mark goes through. Those will
3	have - take more time to analyze some of the
4	longer papers. And so at this point SC&A has
5	completed their action item list and I'll turn
6	it over to Mark unless there's questions on
7	anything that we were to do or have done.
8	MR. ROLFES: Okay, thank you Ron.
9	Yes, as you had discussed I'll just go
10	through the responses that we prepared as a
11	result of the past couple of Work Group
11 12	result of the past couple of Work Group meetings on Weldon Spring Plant. We prepared
12	meetings on Weldon Spring Plant. We prepared
12 13	meetings on Weldon Spring Plant. We prepared responses to SC&A's review about concerns of
12 13 14	meetings on Weldon Spring Plant. We prepared responses to SC&A's review about concerns of documentation for an accident or an incident
12 13 14 15	meetings on Weldon Spring Plant. We prepared responses to SC&A's review about concerns of documentation for an accident or an incident that was issued, 2-7. We've prepared a
12 13 14 15 16	meetings on Weldon Spring Plant. We prepared responses to SC&A's review about concerns of documentation for an accident or an incident that was issued, 2-7. We've prepared a response to the Weldon Spring Plant Evaluation
12 13 14 15 16 17	meetings on Weldon Spring Plant. We prepared responses to SC&A's review about concerns of documentation for an accident or an incident that was issued, 2-7. We've prepared a response to the Weldon Spring Plant Evaluation Report issue number 7 which was comparison of

21 for workers during 1967. The fourth was a

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

124

lack of 1 response on the personnel 2 contamination monitoring. We've also provided 3 Weldon Plant response the Spring а on environmental intake rates and external dose 4 5 previously provided rates and we've an evaluation of the minimum detectable amount 6 7 for uranium urinalyses. Let's see. I don't know if you have questions on what 8 you've 9 looked at so far or if you want me to go through these in a little bit more detail. 10 11 MR. KATZ: Please do.

12 MR. ROLFES: Okay. Well, SC&A 13 provided a list of three claimants to us that 14 had indicated that they were involved in some incidents. And what we found, we went back 15 16 and looked to see primarily if there were 17 bioassay data available to for dose us reconstruction purposes. We did find bioassay 18 data for the three individuals. 19 We looked in 20 our Site Research Database. We searched first "accident," 21 keywords on such as

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

125

1	"contamination," "incident," "intake,"
2	"uptake," "release" and "wound." We found
3	some documents from the operational period.
4	We had referenced 15847 - or excuse me, 874.
5	That's 15874 had approximately 320 uranium in
6	urine results above the Weldon Spring action
7	level in 1960. There were some above action
8	level 2 which would have been 0.1 mg per liter
9	to 0.2 mg per liter and there were some
10	explanations associated with those higher
11	results such as incidents. Let's see. We had
12	another reference, 15865 which contained
13	approximately 150 urine results for 1961 that
14	were over action levels. We had some
15	information on action level 2 urinalyses with
16	some explanations that said that there were
17	high-exposure incident reports, investigations
18	of high-exposure incidents and results of an
19	investigation of high urinary uranium
20	exposure. So it appears when you look into
21	the records that the information we have

NEAL R. GROSS

126

1	available to us does show that there is
2	documentation of incidents available to us.
3	If we don't have per se, you know, something
4	documenting that there was a radiological
5	incident that occurred we do still have the
6	bioassay data available to us and that
7	bioassay data would reflect a significant
8	intake from an incident or accident. Is there
9	any questions or comments about?
10	CHAIRMAN GIBSON: None of the data
11	was out of line as far as exposures?
12	MR. ROLFES: Nothing - I mean, we
13	had different action levels at the Weldon
14	Spring Plant and if an employee had a higher
15	exposure then they would track that employee a
16	little bit closer to make sure that his
17	urinary excretion came down below an
18	acceptable level. They'd pull him out of the
19	work area, for example. We didn't find any
20	inconsistencies that - in the data. Let's
21	see. I'll read our summary here. It says,

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

127

"NIOSH 1 finds that the accident incident 2 information is not available in all cases. 3 However, the specific examples given by SC&A reflect the fact that favorable outcomes for 4 5 claimants are still likely. The work group 6 monitoring method that was used by Weldon 7 Spring does not present an obstacle to NIOSH's ability to do dose reconstructions. 8 In fact, group monitoring 9 the use of work data is 10 likely to result in a more favorable dose estimate." 11

12 There of the were one even _ 13 former health physicists responsible for the 14 site had actually, in order to better explain some urine excretion patterns had ingested 15 16 capsules of uranium sodium diuranate and compared that - he basically ingested 0.11 and 17 10 times the daily limit of sodium diuranate 18 and monitored his urine excretion. 19 I don't 20 know if there's anything else that we haven't 21 identified here that - without reading the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

128

1	entire thing. Any other questions?
2	DR. BUCHANAN: This is Ron
3	Buchanan, SC&A. This came about was that
4	during some of the interviews the workers felt
5	that their accidents were not recorded in
6	their files and because at that time they
7	weren't necessarily considered radiological
8	incidents. A furnace blowout or something was
9	a physical accident they considered at the
10	time. And so my question was I looked at
11	three of the major incidents that was related
12	to me, found the claim numbers and then had -
13	sent those to NIOSH to look to see was the
14	dose reconstruction, you know, did they have
15	bioassay for those incidents. And so although
16	the file, in the worker's file it didn't
17	necessarily always list it as a radiological
18	incident was there data there to reconstruct
19	the dose. And that was the purpose of this
20	exercise. And so you know, this is kind of a
21	subjective thing. Every site comes up with

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

129

1	radiological accidents and incidents, were
2	they recorded and how could you find them, and
3	so I wanted to explore this to a reasonable
4	degree. And I do have a few questions.
5	Number one, I understand that Weldon Spring
6	does not have a list of accidents that you can
7	go to and look at, but you do make the
8	statement that accident information can be
9	found in a global search from the Research
10	Database by last name. Okay. Can you explain
11	a little bit what you're talking about? Can
12	you just put in a worker's last name and
13	they'll come up and give you accidents he's
14	involved in or what are you speaking of there?
15	MR. ROLFES: Within our Site
16	Research Database sometimes the document
17	title, it depends upon the descriptive
18	information put into the Site Research
19	Database. It's very possible that, you know,
20	if there's a significant incident you know
21	there might be an investigation of the high

NEAL R. GROSS

130

1	exposure to such and such. So in that case
2	that's one approach that might identify an
3	incident in addition to looking at, you know,
4	just a keyword search for "accident,"
5	"incident," "contamination." So but we have
6	identified though that not every incident
7	necessarily has a document tied to it. And so
8	there could be an exposure scenario as shown
9	by an individual's bioassay results where they
10	investigated a high exposure. And in those
11	instances there are notes sometimes that say
12	this was a result of such and such that
13	occurred in this plant on this date or
14	something.
15	DR. BUCHANAN: Okay. And then on
16	page 3 of your response you say in fact the
17	use of work group monitoring data is likely to
18	result in a more favorable dose estimate.
19	Would you care to explain the basis of that
20	statement, what you - how you get at that

21 fact?

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

131

1	MR. ROLFES: Okay. Well, the work
2	group monitoring, they actually focused on the
3	people that had the highest potential for
4	exposure within that work group. And I'd also
5	like Bob Morris, Bob, I believe you'd be the
6	right person about the statement regarding the
7	work group monitoring, if you might be able to
8	elaborate a little bit as to why that would
9	result in a more claimant-favorable dose
10	estimate. Is that you, Bob, or maybe Monica
11	would be the other one?
12	MR. MORRIS: I'm not - this is
13	Robert. I'm not prepared to say anything
14	right now.
15	MR. ROLFES: Okay. Monica, might
16	you have anything to add about this?
17	MS. HARRISON-MAPLES: I'm just
18	reading on page 3 of the response I think it
19	kind of summarizes it. It talks about we
20	spoke about the work group monitoring relies
21	on the highest exposures in any given week to

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

(202) 234-4433 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

132

determine - is determined from the work group data. And that's why we're saying it would be favorable because it couldn't - it would be bounded.

5 Well, this DR. BUCHANAN: Okay. How do we extract that? 6 is Ron again. When 7 they do actually do dose reconstruction they look for Worker X, they look for his data, it 8 9 looks for his bioassay data, and does the 10 internal dose assignment using IMBA through 11 his bioassay results. And so I quess what I'm trying to do is connect how the work group 12 13 monitoring would be used for his actual dose 14 reconstruction.

MS. HARRISON-MAPLES: I would not like to really go into that at this time. Liz Brackett was unable to stay on the call, she had to travel today, and she would be the person to speak to that point directly.

20 DR. BUCHANAN: Could we get an 21 answer to that question how the group

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

> > 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

133

monitoring data would be used in an actual
individual dose reconstruction to cover the
group monitoring.
MR. ROLFES: We can certainly do
that. I don't know if when you send your
action items if you could identify that and
we'll certainly -
DR. BUCHANAN: Okay.
MR. ROLFES: - have a response
prepared for that question.
MEMBER LEMEN: I have a question.
You're reading from the report that they sent
you. Have you sent that to the Board Members
too? Because I just asked Mike, he doesn't
remember getting it and I don't remember
getting it.
MR. ROLFES: Was the question for
me?
MEMBER LEMEN: Yes.
MR. ROLFES: I have prepared
responses and sent them out - thank you, Dave.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

134

1	I sent out an email on April 21, 2011 at
2	10:31 a.m. and it contained six attachments.
3	Those attachments are also available on the
4	Advisory Board document review folder under
5	Weldon Spring in a folder titled NIOSH
6	Responses 4/21/2011.
7	CHAIRMAN GIBSON: It went to the
8	NIOSH email address.
9	MEMBER LEMEN: Okay. That's why I
10	didn't get it.
11	MR. FITZGERALD: You can hold on
12	to that for now. I mean, I think I can look
13	over his shoulder.
14	MEMBER LEMEN: Okay.
15	MR. FITZGERALD: What we're
16	talking about is the very last attachment at
17	the very end.
18	CHAIRMAN GIBSON: Okay, so DCAS is
19	going to put together something for that
20	issue. Then you mentioned something else,
21	Weldon Spring operational activities. Was

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

135

1 that? Let's see here. 2 MR. ROLFES: Yes. 3 The next response that we had, let's Okay. see here, let me make sure I've got the right 4 5 one. By the way, 6 DR. BUCHANAN: that 7 was SEC number 8, of accidents and incidents that was just addressed. 8 Okay, let's see. 9 MR. ROLFES: The 10 next one that I have here is regarding a lack 11 of information for workers during 1967. So 12 basically 1967 there operational were no 13 activities ongoing the site. The at - the 14 production shut uranium was down of 15 production operation at the Weldon Spring 16 Plant was shut down December 31, 1966. We 17 have included 1967 as part of the covered 18 period. The Department of Labor has actually 19 approved 1967 as a covered year even though no 20 operational activities were ongoing. So what 21 wanted because there we to do, was not

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

136

1	anything going on there we felt that the use
2	of data from 1966 for the employees that were
3	working at the site in 1967 would be
4	applicable for dose reconstruction if need be.
5	And what we did, we took a look
6	back at - let's see here. Here's - I'll just
7	read our summary statement here. It says,
8	"NIOSH concludes that while the working
9	conditions and thus the exposure potentials
10	were different in 1967 from those during the
11	operational period, SC&A's original statement
12	is not accurate. NIOSH contends that
13	production worker data and environmental data
14	from the production area can be applied to the
15	1967 time period. The work activities and
16	thus exposure potentials at the quarry and
17	raffinate pits were similar before and after
18	the facility shut down. The exposure
19	potential due to the limited maintenance and
20	shuttering operations in 1967 during the
21	transition to the Department of the Army

NEAL R. GROSS

137

1 control of the facility would also be bounded by operational period data." So there were 2 3 concerns primarily about the raffinate pits and guarry exposure potential, and nothing was 4 5 being done in the raffinate pit areas or in the quarry during 1967 so the use of the 1966 6 7 data would provide a bounding intake value or assignment value for 1967 8 dose the time 9 period.

We also did look back at the cases 10 11 that would be impacted and without going into 12 what those cases were I - we queried the NIOSH 13 OCAS Claims Tracking Software database, NOCTS, 14 for Weldon Spring Plant employees to identify claims with employment during 1967. We found 15 16 17 claims with covered employment during the 17 1967 year. We identified those on February 2011. Of those 17 claims five were 18 17. in Special 19 included the Exposure Cohort 20 designation from another site, for example, Mallinckrodt. received 21 Ten dose

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

138

1	reconstructions and had a Probability of
2	Causation of greater than 50 percent, and two
3	had dose reconstructions with a result of less
4	than 50 percent. We looked back at the
5	methodology that was used for those two claims
б	and without getting into the specifics of
7	their dose reconstructions I recall one of the
8	two individuals at least we applied an OTIB-
9	228 radionuclide overestimate and also
10	assigned I believe an overestimate of the
11	individual's external dose. And the approach
12	that we used, we actually assigned that
13	overestimate of external dose for every year
14	that the employee was onsite, even though
15	after 1967 it wasn't a covered site. So we
16	assigned some dose for years that we
17	essentially shouldn't have because they
18	weren't covered. So in that scenario to look
19	back at specific information from a previous -
20	from 1966 for example it would result in a
21	lower dose estimate for that particular case.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

(202) 234-4433 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

139

1	And I don't recall the details of the other
2	one. Let's see if I can take a look here.
3	Monica, was the other case one that we had
4	assigned an environmental intake I believe?
5	MS. HARRISON-MAPLES: That's
6	correct. The other one was a crane operator -
7	MR. ROLFES: Okay.
8	MS. HARRISON-MAPLES: - and we
9	assigned in the internal and external
10	exposures the information from 1966 we felt
11	would extrapolate to 1967 given our
12	understanding of the job responsibilities and
13	what kinds of things were going on at the site
14	at the time.
15	MR. ROLFES: Okay, thank you.
16	MS. HARRISON-MAPLES: You're
17	welcome.
18	MR. ROLFES: Are there any
19	questions about this?
20	DR. BUCHANAN: This is Ron
21	Buchanan, SC&A. Now you're referring to

NEAL R. GROSS

140

1 number 3 on your list, information of dos
2 reconstruction, 1967, correct?
3 MR. ROLFES: That's correct.
4 DR. BUCHANAN: Okay. And wher
5 this comes out, Mike, is that as I was - o
6 course in the meeting I discussed is tha
7 Weldon Spring shut down operations Decembe
8 31, 1966 and then 1967 was a period that the
9 - a gray area, okay? And then between '67 an
10 '69 the Army contracted people to come in an
11 decontaminate and revamp some of the building
12 to do Agent Orange and that never did com
13 about, they closed it down. And so m
14 question was when did the facility actuall
15 transfer over to the Army and NIOSH di
16 provide documentation showing that it wa
17 transferred on December 31, 1967, a year afte
18 the official operation started. Now, th
19 quarry and the pits, the raffinate pits, wer
20 not transferred, just the chemical plan
21 acreage. And so my question was since th

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

141

1	SC&A - SEC went through 1967 what about that
2	year because according to the records I could
3	not find any bioassays or dosimetry records
4	for 1967. And so what NIOSH proposed to do is
5	to use 1966 data to cover 1967 and my
6	contention was, well, they were different
7	situations between the two. Okay, now if 1967
8	was a transition year that not much activity
9	was going on then '66 data would meet or
10	exceed '67 exposures.

11 But trying what we were to get 12 verified was what happened there in 1967. And 13 really the way it stands now is that we have not 14 located, NIOSH has provided not 15 documentation regarding what happened in 1967. 16 At some point they went in and started taking out some of the bricks and that sort of thing 17 and redoing the floor and some people were 18 exposed during that time and NIOSH in this 19 20 paper here contends that that was in March 21 1968 and forward. And so I guess where we

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

142

1	stand is we don't have anything to show what
2	was done in '67 and really hasn't been any
3	information presented showing that nothing was
4	done in 1967. And so that's where it kind of
5	stands is what was 1967, that's why I call it
б	the gray area, what activity was going on
7	there and we haven't found any document that
8	actually shows one way or the other what was
9	going on in '67.
10	CHAIRMAN GIBSON: I think that

clearly needs to be determined because the 11 12 production data - production bioassay data 13 wouldn't necessarily cover period of а decommissioning and decontamination. 14 There 15 could be higher exposures during that period 16 than there are in operational periods.

MR. ROLFES: There was actually no nothing done at the site during 1967 as far as remediation or decontamination of the site. That wasn't done really back until the DOEcovered time period 1975 forward when the Army

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

> > 1323 RHODE ISLAND AVE., N.W.

(202) 234-4433

WASHINGTON, D.C. 20005-3701 www.nealrgross.com

143

1	- do I have that date correct, Monica? Is it
2	1975 when DOE took the property back?
3	MS. HARRISON-MAPLES: I believe
4	that's correct.
5	MR. ROLFES: Okay. But yes, as
6	Ron had indicated there was some individuals
7	that had indicated that there was some work
8	done and we've got in our summary on page 4
9	there were some operations conducted by
10	Thompson-Stearns-Rogers, TSR Incorporated,
11	which were consistent with the preparation of
12	construction for the herbicide facility
13	beginning in March of 1968 under the
14	Department of Army. So that right now is not
15	covered work because it's outside of the DOE-
16	covered employment time period. We didn't
17	find any type of indication of decontamination
18	work that was conducted under the DOE-covered
19	time period at Weldon Spring.
20	CHAIRMAN GIBSON: So there was no
21	information found or I mean is the

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

144

1 documentation complete just that you didn't 2 find any?

3 just MS. HARRISON-MAPLES: Can I 4 say that we did find some memos that were 5 indicative although they were not definitive. They indicated that there were discussions 6 7 going on, there was negotiations going on back and forth between AEC and DOE that seemed to 8 9 imply that the site was in a shutdown state 10 waiting for them to make this transfer, cross i's 11 their t's and dot their in terms of 12 However, there's been absolutely paperwork. 13 indication that find of no we can anv 14 substantive work that was going on at the site during 1967. Ongoing, you know, reviews say 15 16 things like looking at the quarry and the - to 17 make sure that there was no leakage, you know, that kind of routine monitoring would have 18 been continuing and there would have been 19 20 safeguards and security issues in terms of, you know, walking the fences, but other than 21

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

145

1	that we have no indication of any kind of
2	disruptive work going on at the site, nothing
3	that would indicate any kind of decon or
4	decommissioning going on at the site during
5	'67.
6	MR. KATZ: Probably be good for
7	SC&A to put your eyes on that documentation
8	that Monica just mentioned that's sort of
9	suggestive at least that the site was static
10	at the time for that year and didn't have any
11	kind of disruptive activity.
12	MS. HARRISON-MAPLES: Like I said,
13	that wasn't definitive, but that was the
14	indication. That was why I didn't reference
15	
тJ	it.
16	it. MR. KATZ: No, I understand, I
16	
16	MR. KATZ: No, I understand, I
16 17	MR. KATZ: No, I understand, I said it's suggestive.
16 17 18	MR. KATZ: No, I understand, I said it's suggestive. MS. HARRISON-MAPLES: Yes.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

146

1	SRDB?
2	MS. HARRISON-MAPLES: I don't have
3	that in front of me right now but I can send
4	it by email.
5	MR. ROLFES: Monica, this is Mark.
6	I can provide some Site Research Database
7	references here. We've listed them on - I
8	think primarily on page 3. There's a few
9	references here. Let's see. Got some
10	discussion of the 1966 shutdown. There's some
11	documentation regarding transfer of
12	operations, materials, technical records and
13	equipment. Talking about the orderly and
14	thoroughly planned shutdown, SRDB 52726,
15	52759, 52770. And then there is a 1967 memo
16	regarding Weldon Spring disposal. It is noted
17	that extensive decontamination would be
18	required for any other than the building's
19	previous use and that elaborate health
20	precautions and radiation monitoring would be
21	necessary during any equipment removal or

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

147

1	extensive building alteration which implies
2	that neither was ongoing at the time of the
3	memo. That memo was in Site Research Database
4	document 13475.
5	MR. KATZ: What's the date of that
6	memo?
7	MR. ROLFES: 1967.
8	MR. KATZ: And the month?
9	MR. ROLFES: It doesn't - it's not
10	listed here.
11	MR. FITZGERALD: I guess that was
12	Monica on the phone. Are one of those three
13	documents in the memo what you're referring
14	to, one of those documents?
15	MS. HARRISON-MAPLES: Yes.
16	MR. FITZGERALD: Okay.
17	MR. ROLFES: And then there's
18	another one here. It goes on to say, "The
19	lack of any record of health protection
20	oversight by the AEC may also support the
21	implication that extensive renovation work was

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

148

1	not being done at Weldon Spring Plant in
2	1967." The November of 1966 memo, which is
3	SRDB 11806, mentions, "Since the new
4	contractor brought onsite may not have a great
5	deal of competence in the nuclear business it
б	was agreed that AEC staff onsite may have to
7	provide guidance from time to time in matters
8	related to health protection. And if the
9	contractor appears to be having a sustained
10	operation with a relatively stable staff it
11	may be desirable to collect urine samples once
12	or twice, for example during the beginning and
13	conclusion of operations for record purposes."
14	So.
15	MR. KATZ: Sorry, what was the
16	date of that?
17	MR. ROLFES: That one was in
18	November 1966.
19	CHAIRMAN GIBSON: So is there any
20	documentation or such about layoffs or
21	anything during '67? Or did they keep their

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

149

1	full complement of staff?
2	MR. ROLFES: The majority - from
3	looking back, the majority of the claimants'
4	employment from my recollection terminated in
5	1966. We were - we had queried our - excuse
6	me, our NOCTS claims database to look for
7	individuals that were employed during the year
8	1967 and we had identified the 17 cases that
9	were employed during the 1967 time period. So
10	and then I summarized the dose reconstruction
11	outcome or the - whether or not they were
12	included in the SEC. So it came down to
13	essentially two individuals' claims that had
14	employment during 1967 and had a Probability
15	of Causation of less than 50 percent.
16	DR. BUCHANAN: This is Ron
17	Buchanan. The plant actually shut down in
18	December of '66 and operation stopped. There
19	was a few people kept over but the support
20	staff and everything is the way I understand
21	it in the other documents I've read on the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

150

1	history of the plant is that everybody left.
2	You know, there wasn't any secretaries,
3	managers or anything after December 31st of
4	'66. Apparently they - a few people still
5	worked to drain some of the lines and package
6	some of the leftover uranium ore, but there
7	wasn't any operations, there wasn't any
8	uranium metal being made and there was - it
9	sounded like there was no medical staff or
10	health physics staff or almost anything left
11	after December 31st of '66. So '67 wasn't a
12	production or operation or anything like that
13	taking place.
14	I guess the question comes up is

when did they start - when did any employees 15 16 working for AEC, what did they do there in '67 and were they exposed to anything that was 17 worse than '66. If they weren't exposed to 18 anything worse than '66 then the method would 19 20 work. Ιf they exposed to different were 21 conditions, conditions different, the were

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

151

1	they weren't operating, but were the
2	radiologic exposures worse, the same or less.
3	Well, then that's the question that we're
4	looking for, some documentation there in '67
5	that there wasn't any operations that wouldn't
6	be covered by the '66 or '65 extrapolation.
7	These references, I did look
8	briefly at some of these references and
9	unfortunately you know, this isn't one of the
10	matters where - it doesn't really say, you
11	know, it says we plan on shutting down, this
12	takes place, this takes place, but we don't
13	have anything from '68 saying hey, '67 report,
14	this is what happened here in 1967 at the end
15	of the year. We kind of have what they
16	planned on doing in '66, what they were going
17	to do in '67, and then a little bit in '67, a
18	memo or two saying you know, if this happens
19	then we need health physics support and stuff.
20	But we don't have anything in '68 to say hey,
21	in '67 this is a summary of what happened.

NEAL R. GROSS

(202) 234-4433

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

152

1	MR. FITZGERALD: So it doesn't
2	sound like our review or a closer review of
3	these documents is going to provide the
4	definitive answer that Mike was referring to
5	earlier which may not be possible. There may
6	not be documentation that really delineates
7	that.
8	DR. BUCHANAN: Right.
9	MR. FITZGERALD: So we're going to
10	be left with some uncertainty about '67.
11	MR. SUNDIN: This is Dave Sundin.
12	I noticed one of the citations was that the
13	transfer of the site to the Army Corps of
14	Engineers was actually on the 31st of
15	December, '67. So I mean, it seems not too
16	logical that there would be work being done by
17	the recipient of that property until the
18	transfer had occurred.
19	DR. BUCHANAN: That's true, it's
20	just the question. And that's okay because it
21	doesn't cover the Army and it doesn't cover

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

(202) 234-4433

1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701 www.nealrgross.com

153

1	'68. And so the question is what did - did
2	AEC workers do there in 1967 at the plant.
3	MR. SUNDIN: In terms of
4	refurbishing it or changing its purpose.
5	DR. BUCHANAN: Yes, right.
6	MR. SUNDIN: It seems unlikely.
7	DR. BUCHANAN: That would be
8	different from '66. That would exceed any
9	exposure, biological or intake or external
10	exposure. That would be different. That
11	wouldn't be bound by '66 data.
12	MR. KATZ: I think at the end of
13	the day you've got to look at the
14	documentation that you do have and the
15	interviews that you had and make a judgment as
16	to what's the likely story here. I mean
17	because it wouldn't necessarily have any kind
18	of end-of-year report that says here's what we
19	did when we weren't doing anything and
20	whatever. I mean, you wouldn't necessarily
21	have such a report.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

154

1	DR. BUCHANAN: Because there's no
2	staff there.
3	MR. KATZ: Yes.
4	DR. BUCHANAN: Overseeing staff.
5	CHAIRMAN GIBSON: On the other
6	hand, if these claimants in '67 recalled
7	something they were involved in and they gave
8	an affidavit to that point, if the program
9	doesn't have anything to refute that, then
10	their word should be taken as valid.
11	MR. KATZ: I mean I think you
12	weigh your evidence that you have. You can
13	weigh all the evidence that you have as sort
14	of the normal course.
15	CHAIRMAN GIBSON: Right and what I
16	hear DCAS saying is there's a lack of evidence
17	that anything went on. So if you have, you
18	know, documentation or an affidavit from a
19	claimant of what they did and there is no
20	evidence to the contrary you have to be
21	claimant-favorable I think. The program has

NEAL R. GROSS

155

1	to put the weight, you know, in what they're
2	willing to swear to.
3	MR. MORRIS: Ted, this is Robert
4	Morris.
5	MR. KATZ: Yes, Robert.
б	MR. MORRIS: Section 5.1 of the
7	Evaluation Report has one sentence in it. I
8	was not involved in writing it but I can - I'd
9	like to read it for you. It says, "During
10	shutdown several buildings were used for
11	interim storage of drummed yellowcake." So
12	that's in the context of the sentence before
13	it saying shutdown was started in '67 and it
14	was turned over to the Army in August '67, so.
15	MR. KATZ: Thanks, Bob.
16	DR. BUCHANAN: Well, the
17	negotiations took place in August '67. The
18	way I understood the documents that NIOSH
19	referred to it actually took place on December
20	31st of - midnight, December 31st 1967. Yes.
21	MS. HARRISON-MAPLES: Can I just

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

156

1	interject something? The comment about
2	affidavits. One of the interviews
3	specifically laid out some of the work that
4	the person did at the site and they were
5	saying that they did this work in 1967. And
6	it is - if you look at the summary of this
7	documentation I'd like to read a paragraph.
8	"The operation of Thompson-Stearns-Rogers
9	described in SC&A SEC 2010 at 0015 seem to be
10	consistent with the preparations for
11	construction of the herbicide facility that
12	began in March of 1968 under the Department of
13	the Army. As described in the Site Profile,
14	the Army began decontamination and equipment
15	removal in buildings 103 and 105, used a high-
16	pressure hot water solution containing an
17	acidic wetting agent to partially
18	decontaminate the buildings and remove
19	portions of some concrete floors to be covered
20	with tar and new concrete. This description
21	is consistent with the work described by the

NEAL R. GROSS

157

1	EE interviewed by SC&A as that having been
2	done by TSR between '67 and '69. NIOSH has
3	not located any exposure records for the work
4	by TSR but the EE interviewed by SC&A
5	described monitors and removals of workers
6	from the building. This is indicative of some
7	oversight for health and safety. Assuming
8	this work was performed for the Department of
9	the Army it would logically follow that such
10	oversight would have also been directed by the
11	Army. Work performed by contractors to the
12	Department of the Army would not be eligible
13	for dose reconstruction under EEOICPA."
1 /	I point that out because the

14 point that because Ι out the 15 person that was interviewed said that the work 16 was done between '67 and '69 and it sounds 17 like we do have documentation supporting what this person said. The only question is when 18 exactly the work was done and I think that's 19 20 the judgment that has to be made is whether 21 this '67 in which have was we no

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

158

1	documentation, we have no indication of
2	anything going on in '67, or if as it states
3	in this other document, if that work was done
4	in March of '68. That's all.
5	MR. KATZ: Thank you, Monica, I
6	think that's helpful.
7	CHAIRMAN GIBSON: Okay, is there
8	any other issues that DCAS responds to or put
9	out reports or White Papers on?
10	MR. ROLFES: Yes. Let's see here.
11	We've got four more here. Let's see. I
12	don't know what order I gave them to you in
13	before but let's see. This one was the -
14	regarding the lack of personnel contamination
15	and egress monitoring. We have provided a
16	short response here. Some of the things you'd
17	need to consider if you were concerned about
18	an individual being contaminated with uranium,
19	you know, you'd have to take a look at the
20	probability that an individual - well
21	basically, first of all if, you're concerned

NEAL R. GROSS

(202) 234-4433

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

159

1 about skin contamination, the dose rate from skin contamination from uranium is usually not 2 3 of concern in comparison the direct to radiation from working with large quantities 4 5 of uranium. If an individual is significantly contaminated it's pretty unlikely that they 6 7 would have contamination exclusive to one portion of their body. So it increases 8 the 9 likelihood probability or the that an individual would have also contaminated their 10 if individual had 11 badge. And an а 12 contaminated badge that dose from the 13 contamination on that badge would be recorded. 14 So it's necessarily unmonitored not an 15 exposure.

We've also discussed some of the radiological control practices to minimize the possibility of skin contamination. And these are on page - I think it's page 3 here of our response. And this, let's see. The measures involved instituting a work permit program

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

160

1	which was aimed primarily at protecting
2	maintenance workers in hazard areas which
3	involved establishing time limits and
4	conducting survey meter checks for areas with
5	radioactive materials. The second was
6	conducting investigations and counseling to
7	study causes for exposure trends or unusual
8	individual exposures and also to educate
9	employees about protective measures. The
10	third was protective shielding, semi-remote
11	operations and worker rotation to control
12	exposure. The fourth was providing work
13	clothing from the skin out for personnel
14	working in regulated areas where radioactive
15	materials were processed and handled which
16	could not be worn outside of the production
17	area except under cover clothing. The use of
18	respirators is specified by the Mallinckrodt
19	health department and six, instituting a job
20	time limit program for personnel who worked
21	routinely in areas where the exposure rate was

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

161

1	known to be above AEC-based tolerance limits.
2	I think that covers. Let's see if there's
3	anything else. Monica or anyone on the line,
4	do you have anything to add to my brief
5	summarization?
6	MS. HARRISON-MAPLES: I don't have
7	anything to add.
8	MR. ROLFES: Okay, thank you. Are
9	there any questions regarding our response
10	here?
11	DR. BUCHANAN: This is Ron
12	Buchanan, SC&A. Mike, this came up because
13	contrary to you know like today's facilities
14	where you go through a hand-and-foot monitor
15	and that sort of thing when you left that
16	Weldon Spring didn't have any egress
17	monitoring for contamination. They did have
18	showers and they did have - provide work
19	clothing to be changed, however. During some
20	of the interviews the concern was that the
21	workers could - it wasn't rigidly enforced and

NEAL R. GROSS

162

1	they could leave without integral monitoring
2	as far as a final point. There might have
3	been some monitoring inside for growth
4	contamination stuff but there wasn't any
5	individual hand-and-foot monitor, that sort of
6	thing, either to go into the cafeteria, the
7	offices or go out through the parking lot and
8	leave. And so, you know, we brought this up
9	as a point of - the fact that the workers
10	weren't egress monitored, and main concern was
11	the uranium in folds of the skin which would
12	concentrate and perhaps cause irradiation that
13	wouldn't be detected on the badge which would
14	be on the chest. And now contrary to the
15	point brought up here, I don't think that it's
16	ever been - I've never seen any scientific
17	studies showing where a contaminated badge
18	gave any sort of correlation to body dose or
19	skin dose. But that aside, this is a common
20	problem at most older uranium sites and so one
21	suggestion at the last meeting was that NIOSH

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

163

1 look at what was done at Mallinckrodt which is a very similar facility and Bethlehem Steel 2 3 which had the same issues. And according to their response and from what I've found, you 4 5 know, that Weldon Spring operated the same as 6 the others did for that time period when 7 material was handled. And so it's more of a global issue than a site-specific issue for 8 9 Weldon Spring and so I don't have any solution 10 on how you would correct the - the thought. And during 11 We can't go back and correct it. 12 reconstruction there are programs for dose 13 bare skin and that sort of thing that 14 calculates skin dose. And so it was a point 15 that was brought up, that there was that 16 lacking egress monitoring at Weldon Spring, 17 but I don't have anything more to add than what's been discussed so far. 18

19 CHAIRMAN GIBSON: It seems also 20 the issue that if there was a problem with 21 skin contamination that could result in

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

164

1	additional intakes too.
2	DR. BUCHANAN: Yes, that was -
3	right.
4	MR. ROLFES: Go ahead. That's
5	correct.
6	DR. BUCHANAN: Yes, there was one
7	that was brought up. Go ahead.
8	MR. ROLFES: Yes, that's correct.
9	And if there is, you know, intake from you
10	know eating something with uranium
11	contamination on your hands for example when
12	we would estimate the intake of uranium using
13	the individual bioassay data that route of
14	intake from ingestion would also be detected
15	or measured by the bioassay results. So when
16	we complete a dose reconstruction, however,
17	it's more claimant-favorable to assume that
18	the uranium was inhaled rather than ingested
19	because it results in a higher internal dose
20	estimate for the claimant. So we wouldn't
21	assume that the individual was ingesting

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

165

uranium because that wouldn't result in the
 bounding dose values.

3 KATZ: Ι ask legal MR. Can а question, Jenny? And maybe it's something you 4 5 already handle in dose reconstructions quys theoretically 6 but iust if someone has contaminated clothing and brings it home and 7 say you know, spends the day in their clothing 8 or what have you, you're offsite, you're off 9 10 the DOE site, is that a covered - is that 11 actually a covered exposure at that point when they're not on site? How does that work? 12 13 MS. LIN: Well, if NIOSH isn't

able to distinguish the dose value when the 14 contamination actually happened at home or is 15 16 it a continuous contamination at workplace or 17 at home, then we have to estimate that dose. But if it's something - this is very different 18 saying something that distinct 19 than is a 20 exposure offsite.

21 MR. KATZ: I see. So if they

(202) 234-4433

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

166

1	bring contamination with them home you cover
2	that exposure -
3	MS. LIN: If we can't distinguish
4	it.
5	MR. KATZ: If you can't. If they
6	were to stay - for example, we've heard
7	stories of in one case of someone bringing a
8	contaminated item home in their pocket or what
9	have you. You would cover that exposure
10	offsite?
11	MS. LIN: I mean, NIOSH is using
12	the kind of -
13	MR. ROLFES: I was going to relay,
14	you know, there's also been occurrences where
15	individuals have brought their film badges
16	home and placed them in a little orange dish,
17	Fiestaware, for example, that contains uranium
18	in it and it's resulted in some elevated doses
19	to that person's badge in excess of you know
20	workplace controls and such. So situations
21	like that have been investigated by health

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

167

1	physics staff to try to understand or you know
2	figure out where that exposure came from and
3	it turns out in some instances those were from
4	employees putting their film badges into
5	Fiestaware bowls. So there's I guess
6	different - it would be a little more
7	difficult to sort out when an intake occurred
8	using bioassay data. If for example it was an
9	external dose it'd be a little bit easier to
10	you know for example, if a person went to
11	another facility that isn't a covered facility
12	and received a bunch of external dose, that
13	wouldn't be covered. However, if they were
14	potentially exposed to uranium at another
15	site, for example, a mill that isn't covered,
16	yet they work at the Weldon Spring Plant and
17	come and get a bioassay data - a bioassay
18	taken and the data shows that they were
19	positive, you know, there was a positive
20	exposure to uranium, if we had no indication
21	that that work was done at some other non-

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

168

1	covered site we would include it and assume
2	that it occurred at Weldon Spring.
3	MR. KATZ: I mean, I was just
4	thinking of the simple situation you have skin
5	contamination, you spend the next 12 hours
6	with that skin contamination offsite, so.
7	MR. ROLFES: Yes, as far as that's
8	- that's more of a legal question rather than
9	a dose reconstruction question.
10	MS. LIN: I think what Mark is
11	describing is a more consistent approach
12	towards dose reconstruction. If we can't
13	distinguish when the intake occurred.
14	MR. KATZ: Yes, it's not intake in
15	this case. It's skin contamination.
16	MS. LIN: Well, but still I'm
17	talking about what you absorb into your body.
18	If you can realistically say well, 20 percent
19	of this happened -
20	DR. MAURO: There's a lot of
21	dialogue that's not coming across the

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

169

1	tel	ephone	

2 MR. KATZ: Okay, I think that's 3 just because some folks are a little more 4 remote from the audio.

5 MS. LIN: So whether Ι mean, 6 that's leqal question technical а or а 7 question, I mean, NIOSH has followed a very consistent approach and using a very claimant-8 favorable bounding calculation. 9 So we'd be more comfortable with that. 10

11 MEMBER LEMEN: I have a question related to that. I think I know the answer. 12 13 In relation to taking clothing home continuing be contaminated, contaminating the home. 14 to Are any family members? They're not covered 15 16 under this at all, are they?

17 MR. KATZ: No.

18 MEMBER LEMEN: So there's no claimant could be given to the family members 19 20 though the family members even may have received a dosage. 21

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

170

1	MR. KATZ: That's correct. It's
2	not covered.
3	MEMBER LEMEN: That's what I
4	thought.
5	CHAIRMAN GIBSON: That's where
6	lawyers get involved.
7	MR. KATZ: Okay, I was just trying
8	to understand where this leads, this question
9	about skin contamination if it's contamination
10	offsite.
11	CHAIRMAN GIBSON: Okay, anything
12	else on that issue? And if not, do we want to
13	continue on? Do we want to break for lunch?
14	Just how does everyone feel?
15	MR. ROLFES: It's up to you guys.
16	I don't know if you would like to work
17	through lunch. We've got three more topics.
18	Two of them are small and I think we discussed
19	one of the two previous. The third and final
20	one is the environmental intake rates and
21	external dose rates, and I think these are

NEAL R. GROSS

171

1	directly responsive to some of SC&A's previous
2	questions about environmental exposures from
3	site operations. I don't know, that's up to
4	you to decide. I mean, I can do whichever you
5	like.
6	CHAIRMAN GIBSON: If there's no
7	objections we'll just work on through.
8	MR. KATZ: For the record, Bob
9	Presley has dropped off the call.
10	MR. ROLFES: Let's see here. I
11	guess we can go ahead to the NIOSH response to
12	SC&A SEC issue number 7 on the quarry and
13	raffinate pit exposures. Monica, I'm probably
14	going to need some help from you to introduce
15	this one. Sorry if I'm putting you on the
16	spot.
17	MS. HARRISON-MAPLES: That's okay.
18	I was just hoping we would take a break.
19	MR. KATZ: Why don't we take a 10-
20	minute comfort break.
21	MS. HARRISON-MAPLES: A 10-minute

172

1	comfort break would be very good right now.
2	MR. KATZ: Absolutely.
3	MR. ROLFES: Okay, sorry about
4	that. Good suggestion, Monica.
5	(Whereupon, the above-entitled
6	matter went off the record at 12:07 p.m. and
7	resumed at 12:20 p.m.)
8	MR. KATZ: Okay, we're coming off
9	of a short break. Weldon Spring Work Group.
10	Where are we?
11	MR. ROLFES: All right. Thank
12	you, Ted. This is Mark Rolfes once again and
13	we were getting ready to introduce our
14	response on the quarry and raffinate pit
15	exposures at the Weldon Spring Plant. And
16	basically we have the quarry where the
17	materials were disposed of. You know we have
18	some indication that some drums of material
19	were dumped into the quarry. They were
20	encapsulated at the time that they were dumped
21	in, however, could have degraded over time.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

173

1	We felt that the operational data that we have
2	available to us would bound any potentially
3	unmonitored exposures during the years that
4	the quarry and raffinate pits are still
5	covered facilities but that the main
6	production facility at Weldon Spring Plant was
7	no longer a covered facility. So we're
8	talking about the 1967 period. Let's see, I
9	don't recall. And then I don't recall -
10	Monica, this is where I need your help. The
11	dates for the covered facility right now for
12	Weldon Spring Plant are '57 through '67 and
13	the AEC retained ownership of the raffinate
14	pits and the quarry. Could you -
15	MS. HARRISON-MAPLES: That's
16	correct, they retained - well, they retained
17	direction for the raffinate pit and the quarry
18	for the whole time up through '85 I believe.
19	MR. ROLFES: Okay. Could you - I
20	didn't really speak to the exposure scenarios.
21	Could you maybe detail a little bit you know

NEAL R. GROSS

(202) 234-4433

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

174

1	the exposure potential and operations being
2	conducted at the quarry during the covered
3	time period versus - well excuse me, during
4	the Weldon Spring Plant proper's covered time
5	period versus.
6	MS. HARRISON-MAPLES: The data
7	that we have?
8	MR. ROLFES: Yes.
9	MS. HARRISON-MAPLES: Yes, I can.
10	We were specifically asked about the
11	operation - the comparison of the operation at
12	the quarry and the raffinate pit compared to
13	the data from '76 and '80 which we rely on
14	relatively heavily and what's the
15	justification for why that data is applicable
16	to the operational period. But just as we
17	were asked for more detail on the operations
18	at the quarry and the raffinate pit. So
19	that's what this response is attempting to
20	deliver. At the quarry there's a pretty
21	detailed I think description of operations

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

175

1 starting in about '59 when thev started 2 constructing a dyking system at the quarry. 3 Then sometime in the early '60s is when the Destrehan Street plant rubble was delivered to 4 There's - and in '63 barrels of 5 the quarry. radioactive waste material were delivered to 6 7 the quarry. So basically we just tried to summarize in one place what all was going on 8 over the operational, you know, the years that 9 are considered operational for Weldon Spring 10 in terms of the rest of the plant. 11

operations didn't 12 Those really 13 change between those years and on down the road the whole time that the AEC maintained 14 responsibility for the quarry, 15 and let me 16 handle these two separately if I may. The 17 quarry was the repository, it was a place where materials had been deposited. 18 There was no operational activity. It is an outdoors 19 20 facility obviously. There are no enclosed The question also arose having to 21 structures.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

176

1	do with radon exposure to the quarry and why
2	we applied environmental kinds of exposures
3	and the answer is because it is an outdoor
4	facility. We provided one schematic, a cross-
5	section of the quarry and sort of tried to lay
6	out where things were deposited, the drums
7	versus the debris, that kind of thing. Then
8	basically the answer to the question that was
9	asked is yes, we do believe that the later
10	data is still applicable because of the in-
11	growth within the material that would have
12	been deposited of radium daughters would have
13	made that a conservative estimate as opposed
14	to underestimating any potential exposure.
15	As far as we know there were only
16	a very limited subset of personnel that would
17	have been putting in any time, any significant
18	amount of time at the quarry as well,
19	environmental monitors and security staff,
20	other than when materials were actually being
21	deposited at the quarry. So those kinds of

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

177

1 op	perations didn't necessarily change. Well,
2 ac	ctually they didn't continue on very much.
3 Th	nere was some additional dumping in the
4 qu	arry by the Army at some point but as far as
5 AE	EC exposures they should not have changed.
6	Then the raffinate pit is actually
7 ki	Ind of a similar story except that there
8 sh	nould not have been any additional or any
9 ad	ditions to the raffinate pit after the
10 op	perational years other than I believe the
11 Ar	rmy was allowed to put some materials into
12 be	efore, after the ceasing of AEC plant
13 op	perations at Weldon Spring. The question has
14 be	een brought up that the material - the
15 ch	nemical composition would have changed, may
16 ha	ave changed and I can't find any
17 ju	astification for believing that it would
18 ha	ave. Basically the plant operated and
19 ra	affinates were delivered into the raffinate
20 pi	It through the piping system and at the
21 ce	essation of operations it would have stopped

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

178

and the material just would have been sitting
 there in the raffinate pit.

3 As far as the exposure conditions at the raffinate pit, it would not have been a 4 5 high exposure potential place because of the 6 nature of the pits themselves. My 7 understanding is that it was kind of а quicksand type consistency 8 so you couldn't 9 really walk out into the pits or there was not 10 any monitoring out over top of the pit. Ιt was a sludge kind of a material. 11 I can't remember any other specifics. 12 The primary 13 hazard would be if there were any dusting from 14 the pits drying out and we found different studies that said that the raffinates were 75 15 16 percent water in 1967, had effectively zero 17 communication with groundwater at the time and that the pits had up to several feet of water, 18 from several inches to several feet of water 19 20 over the surface throughout the year was one reference that we found. 21

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

179

1	In 1974 there was the
2	environmental assessment stabilization of the
3	raffinate pit. It said that they were
4	constantly underwater and the residue the pits
5	went into even in the dryer - needed to stay
б	moist, the areas around the pit and levees.
7	So that was our understanding as of the end of
8	the operational period which is what we were
9	asked about, what were the activities there
10	and what sort of exposure conditions were
11	there during the operations period and why we
12	felt that the later data was representative.
13	Are there any questions?
14	DR. BUCHANAN: This is Ron. Do
15	you know if the pits were fenced during
16	operation? Do you recall reading anywhere
17	about that?
18	MS. HARRISON-MAPLES: I believe
19	they were. The pits were somewhat segregated,
20	they were off to one side of the facility. I
21	believe, I've got a schematic here in this

NEAL R. GROSS

(202) 234-4433

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

180

1	response document, yes. So they were part of
2	the plant but they weren't integral to the
3	plant, they were off on one side. Yes, they
4	were fenced. The quarry was also fenced.
5	DR. BUCHANAN: Okay, the - this is
6	Ron, SC&A. The reason this question was
7	brought up was that was there a difference in
8	the operation of the quarry and the pits after
9	the closedown of the plant and also during the
10	plant that it would be different than
11	measurements taken later on. They did take
12	parameter measurements of uranium by air
13	samples, but there wasn't during operations
14	'57, during the SEC period '57 to '67 there
15	wasn't any air measurements around the quarry
16	or the pits in themselves and the question
17	that we raised. And so what they did was they
18	used, when they started to, you know,
19	remediation, before they did that they took
20	samples and they have samples during the '70s
21	and '80s to extrapolate - NIOSH extrapolated

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

181

1	those back to the '60s. And what SC&A's
2	question was, was there any major difference
3	between the pits and the quarries during the
4	operational period compared to when the
5	samples were taken or would that bound the
6	exposures during the operational period. And
7	so that's the reason we raised the question
8	and at this point we don't have anything that
9	indicates, you know, that there was a major
10	difference in exposure between the two
11	periods. We don't have anything that
12	indicates that that wouldn't be usable and
13	what NIOSH was supposed to do was to look at
14	and see if there was any major difference
15	between the two periods.
16	CHAIRMAN GIBSON: Any questions on
17	that? Okay.
18	MR. ROLFES: All right. Thank
19	you, Monica, for the -
20	MR. KATZ: Is that item closable
21	at this point?

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

182

1	CHAIRMAN GIBSON: Yes.
2	MR. ROLFES: Okay. We had
3	previously sent - we were asked a question by
4	SC&A about our basis for a limit of detection
5	for fluorometry which was the method used to
6	analyze urine samples for their uranium
7	content. We provided a brief 3- or 4-page
8	explanation of how that 0.08mg per liter
9	minimum detectable amount value was calculated
10	and we've basically shown an equation to
11	calculate the minimum detectable amount where
12	you multiple a factor of 3.29 times the
13	standard deviation of blank samples and divide
14	that value by a calibration factor. That
15	gives us a value of about 0.07mg per liter and
16	supports the justification for our use of
17	0.08mg per liter for uranium in urine. Oh,
18	0.007, thank you Dave. I said 0.07, but
19	that's 0.007mg per liter or 7 micrograms per
20	liter. I guess if there's any questions.
21	The significance of this I guess,

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

(202) 234-4433

1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

183

1	if an individual has a urine sample that's
2	reported in their file that is less than
3	0.008mg per liter we would assign a missed
4	intake by actually assuming that they had a
5	value less than the MDA and we would default
6	to one-half of that MDA value of 8mcg per
7	liter. We would give them credit for a
8	potential exposure even though they didn't
9	have a positive bioassay. So that's.
10	DR. BUCHANAN: This is Ron of SC&A
11	again. This was not a SEC issue, this was a
12	Site Profile issue number 21. And this was
13	brought up because TBD didn't really - a good
14	explanation to where this number came from and

1 1 1 14 explanation to where this number came from and 15 so that's the reason we asked for it and I 16 have no problem with their explanation. I did 17 have question on page 3 of vour last а 18 sentence there. It says the MDA calculated from the - well actually, blank value of 0.008 19 20 is of no practical use in these circumstances. That last paragraph, are you going to use the 21

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

184

1	one-half MDA or why is that put in there? I
2	didn't follow that.
3	MR. ROLFES: Well, I think for
4	claim-specific information if an individual
5	has a value of less than 8mcg per liter then
б	we would apply an intake equal to one-half of
7	that MDA value to calculate their missed
8	uranium intake. I don't know if we have the
9	author. Mel, is Gene available to respond
10	regarding Ron's question?
11	DR. CHEW: I think Gene's on the
12	line.
13	MR. ROLFES: Gene?
14	MR. POTTER: This is Gene Potter
15	from the ORAU team.
16	MR. ROLFES: Hi Gene.
17	MR. POTTER: Yes, that last
18	statement probably should not have been
19	included. It was merely intended to - one
20	thing that Mark didn't discuss is that we
21	looked at the pre-job samples and showed that

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

185

1	there was a 50 percent probability - to a log-
2	normal is 50 percent probability that an
3	unexposed worker would have a value of
4	0.0036mg per liter or greater as an unexposed
5	worker. So it amounts to about the same
6	thing, something like assigning an MDA or a
7	half of the MDA of 0.008. So I can see how
8	that, taken by itself is not - it's not - was
9	not intended to be a statement about how dose
10	reconstructions are done.
11	DR. BUCHANAN: Okay, so what was
12	intended there was saying that one-half MDA is
13	about the same as the non-exposed worker's 50
14	percent value.
15	MR. POTTER: That's correct.
16	DR. BUCHANAN: Okay. Okay, no
17	problem.
18	MR. ROLFES: Thank you, Gene. Any
19	other questions on that one? Okay. The last
20	response that we prepared -
21	MR. KATZ: That item is closed,

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

186

1	just for the record.
2	MEMBER LEMEN: Yes.
3	MR. ROLFES: The last item that we
4	prepared in response to SC&A's review was I
5	guess SC&A had some comments about how the
б	environmental intakes were assigned at the
7	Weldon Spring Plant. This contains some
8	updated information on our proposed
9	environmental intake rates as well as external
10	dose rates. There were some comments about
11	the radon exposure potential. We've addressed
12	the radon exposure potential in here. Let's
13	see, I'm trying to think of any other specific
14	things that. Let's see. Oh, this is 38 pages
15	long here and I don't want to go through point
16	by point, but if there's specific questions we
17	can try to focus on those.
18	DR. BUCHANAN: Okay.
19	MR. KATZ: It would be good to
20	have an overview at least at some level.
21	MR. ROLFES: Okay.

187

1	MR. KATZ: To tee up the -
2	MR. ROLFES: All right. Well,
3	let's see here. I'll just go through some of
4	the brief tables in here and that'll try to
5	capture the important data because that's
6	where we've got -
7	MEMBER LEMEN: Is there a summary
8	of it? Don't you just have a summary there at
9	the back? That'd probably be easier.
10	MR. ROLFES: I don't believe we
11	have a summary in this document. The tables
12	are probably our best bet for the
13	summarization of - I guess that's the end
14	product of the doses that we'd be assigning or
15	the intakes that we'd assign. And this is
16	just off of page 3 of 38. We've got tables in
17	here that have the average airborne
18	particulate and radon concentrations at the
19	Weldon Spring chemical plant, the raffinate
20	pits and the quarry. We have a table which is
21	the estimated average annual inhalation intake

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

188

1	of radioactive air particulates and radon at
2	Weldon Spring chemical plant, the raffinate
3	pits and the quarry. We have estimated
4	ambient onsite dose for each of those same
5	three facilities. We have the estimated site-
6	wide maximum inhalation intake of radioactive
7	air particulates and radon at Weldon Spring.
8	And a table, the fifth table in here is the
9	estimated maximum site-wide ambient dose at
10	Weldon Spring Plant. And I could ask maybe
11	Bob and/or Billy if there's any details. I
12	know radon was one of the key issues that we
13	had updated in this site - or in this White
14	Paper here from our previous version of our
15	Site Profile. But might you have anything to
16	add about any significant changes from our
17	previous Site Profile to what we currently
18	have in this White Paper?
19	MR. MORRIS: This is Robert
20	Morris. I would say that there is an

21 interesting change or two, that it's going to

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

189

1	be hard to describe in enough detail to
2	satisfy right now, but it's all documented now
3	in this paper. What we've done is taken the
4	perimeter air monitoring data and using a
5	Gaussian plume dispersion model we've reversed
6	the flow so that we can predict the
7	concentrations near the center of the
8	operating facility based on the perimeter data
9	that were measured. And it's sort of like
10	going backwards from a smokestack to a
11	perimeter, we're going - going from the
12	smokestack to the perimeter, we're reversing
13	that process and using - just solving the
14	equation backwards. So what you come up with
15	is a relatively large and consistent set of
16	perimeter data that we can then use to infer
17	the concentrations in the operating area, and
18	that's where the intake rates come from.
19	MR. ROLFES: Thank you, Bob. I do
20	recall now that you say that that we had a
21	discussion about which particular assumptions

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

190

1	we would use and whether we would use, you
2	know, what type of dispersion model we were
3	going to use and such.
4	MR. MORRIS: Yes, I guess I'd just
5	add to that we've been mindful of the comments
6	that SC&A has made over the years about which
7	kinds of dispersion factors to use, where
8	they're drawing from and we got these from the
9	NRC recent assumptions that seem to be in
10	favor at this point. And I think that you
11	know, although you're certainly dependent on a
12	model to go backwards we did use the Lambert
13	Field St. Louis met. data and came up with
14	what looks to me to be a fairly conservative
15	claimant-favorable approach to this problem.
16	MR. ROLFES: Thank you, Bob.
17	MR. MORRIS: You're welcome.
18	CHAIRMAN GIBSON: If I'm not
19	mistaken – aren't calculations you come up
20	with from dispersion models and everything
21	else, isn't that mainly for environmental or

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

191

1 public exposures or readings and stuff like 2 that?

3 Well, this is - these MR. ROLFES: are environmental exposures that we're talking 4 about so these are basically for an individual 5 who was not monitored at the site essentially. 6 7 And what we've done, we've used data from the perimeter of the site to basically model back 8 to in-plant conditions or conditions on the 9 10 outsides of buildings for whom if there was 11 some employee that was onsite that wasn't a radiation worker, for example, who could have 12 13 potentially been exposed to something above 14 background levels have modeled this we approach to assign intakes to that individual. 15 16 CHAIRMAN GIBSON: Т understand 17 that calculation, but that still to me just seems to be kind of a stretch that - to use 18 19 that as opposed to some recognized type of 20 worker monitoring.

21 MR. MORRIS: This is simply

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

192

1	supplemental to the existing data that
2	otherwise wouldn't be used, and so we're just
3	using it to inform the rest of the
4	information. I refer you to a spreadsheet
5	that was carefully done to support all the
6	data tables in this intakes rate paper that
7	we're talking about. And I don't think you
8	can actually understand how we got from that
9	without reviewing the spreadsheet. But we
10	were careful to document it in the spreadsheet
11	for you so I'd encourage you to look at them
12	both at the same time.
13	MR. ROLFES: Bob, in referring to
14	the spreadsheet here, is this the last page
15	here that we're referring to of our response,
16	page 38?
17	MR. MORRIS: Let me see. I don't
18	recall how it actually ended up being edited
19	SO.
20	MR. ROLFES: Okay. This was
21	primarily related to the radon concentrations

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

193

1	for the Weldon Spring Plant buildings and this
2	was really the one where we focused on. I
3	think most of the effort was related to and
4	most of the concern was also related to radon
5	exposures. So I think that's - this is going
6	to be one of the primary things that we needed
7	work, or this was one of the things that we
8	didn't have as much documentation on in our
9	previous version of the TBD. And I think SC&A
10	had pointed out we had quite a bit of
11	discussion about how much of the radon release
12	outside of the buildings could have been
13	potentially brought back into the buildings
14	and I believe we had assumed that, correct me
15	if I'm wrong someone out there, but I think we
16	believe that you know 100 percent of the radon
17	that was released was brought back in via the
18	ventilation system. Is that correct?
19	MR. MORRIS: We, I think we all
20	converged to the idea last time that that
21	would be a claimant-favorable assumption, that

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

194

1	really didn't depend on modeling the wake
2	effects or anything else. And so as I recall
3	that was the successful conclusion about the
4	inside concentration based on that.
5	MR. ROLFES: Okay.
6	MEMBER LEMEN: When you mentioned
7	the samples taken at Lambert were those simply
8	for background comparison?
9	MR. MORRIS: When I talked about
10	Lambert Field I'm talking about the
11	meteorological data that is taken for the
12	Weather Service.
13	MEMBER LEMEN: Okay. Not anything
14	with background or anything like that.
15	MR. MORRIS: No, it was simply in
16	order to - what the typical wind speed, wind
17	direction -
18	MEMBER LEMEN: Okay.
19	MR. MORRIS: - the parameters that
20	you need to run a simple Gaussian plume model
21	_

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

195

1 MEMBER LEMEN: Okay.
2 MR. MORRIS: - are - across by
3 ordinary data sets like that.
4 MEMBER LEMEN: Okay. Thank you.
5 MR. MORRIS: You're welcome.
6 DR. BUCHANAN: Now what
7 spreadsheet - are you referring to Appendix A
8 on page 38 or are you referring to something
9 that's on the Research Database or something?
10 MR. MORRIS: Ron, it was posted
11 with the White Paper right next to it and
12 provided to you at the same time. It's
13 titled, at least the title that I've got is WS
14 Environmental Intake rate. And so you can
15 look for that and read that spreadsheet at the
16 same time you read the White Paper.
17 The logics, you know, what
18 happened between this year and that year
19 because sometimes we had different data sets
20 and so we put a flow chart in so that you
21 could figure out how we got from, you know,

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

(202) 234-4433

1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

196

1	some years we had gross alpha data, some years
2	we had uranium data, some years we had radon
3	data. If you don't have this decoder ring
4	you're not going to be able to figure out
5	where the number came from that got posted
б	into the table.
7	DR. BUCHANAN: Okay. Could I ask
8	some questions then?
9	MR. ROLFES: Sure.
10	DR. BUCHANAN: I guess Bob, he's
11	the one that has the details, if you don't
12	mind. This is Ron, SC&A. The question that -
13	I just had a chance to read over this a time
14	or two. We haven't done a thorough
15	evaluation. I guess on - are you saying, I
16	think it's on page 14, that the thoron
17	concentration was much, much less than the
18	radon concentration and therefore you weren't
19	going to model that. Is that what the third
20	paragraph on page 14 is saying?
21	MR. MORRIS: I'm sorry, my

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

197

1	government computer is really slow, I can't
2	even page up or down right now. So I can't
3	tell you what's on page 14 right now.
4	DR. BUCHANAN: Okay.
5	MR. MORRIS: But it seems to me
6	that that's correct. There were some times
7	when the concentrations of radon were so small
8	that we said we're not going to - they're
9	negligibly - they're negligible. My
10	computer's locked up, sorry.
11	DR. BUCHANAN: Okay. Well, on
12	page 14 when you do get to look at it, it
13	looks like you're saying that the radon-222
14	release could approach 70 percent of the
15	radon-222. The 220 could be 70 percent - the
16	222. However, if I go through your
17	calculations it looks like more like 3
18	percent. That was a question I have but if
19	you can't read that I can't discuss that with
20	you.
21	MR. MORRIS: I'm sorry, my

MR. I'm MORRIS: sorry, my

> **NEAL R. GROSS** COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

198

1 computer just won't respond to me right now. 2 So all I can tell you is we were very careful 3 and if we didn't get the data in the logic chart that's in that flow sheet for how we got 4 the numbers then that's certainly we need to 5 6 revisit. But you should be able to follow 7 through from any given point in the table back assumptions were 8 what our from our up to spreadsheet. 9

10 DR. BUCHANAN: Also, Okay. you 11 have your tables, you have tables 1 through 5 and table 2 I believe is the intake according 12 13 to the major facilities. Let's see. Yes, the 14 the plant and the quarry. pits, And you'd for different 15 have years and uranium and 16 thoron and that sort of thing, tritium. And 17 then in table 4 it says maximum intakes. Now, I would assume that means that you selected 18 19 the intake for that year from those three 20 major facilities and entered it in there that 21 that would be maximum intake. Is that

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

199

1 correct?

2 MORRIS: Yes. We wanted to MR. 3 simplify it for the dose reconstructor. So we each facility had 4 documented what as the 5 maximum concentration or intake excuse me, 6 rate. And then we said okay, which of the 7 columns on this line give us the highest 8 value. That's the one we posted for the 9 assumption, for the default assumption for 10 that year.

11 DR. BUCHANAN: Okay. Well, I went through that and it didn't appear that that's 12 13 what happened. For example, 1957, uranium is 1^3 in both tables but thorium-230 is 8.2 times 14 10^2 and on the maximum chart it's only 7.1 15 times 10^2 . 16 And so I just wondered if I'm 17 reading this wrong or is there an error in filling in that maximum or something. 18

MR. MORRIS: I don't know from offthe top of my head right now.

21 DR. BUCHANAN: Yes. Well, that

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

200

1	would be one thing. I'd like for NIOSH to
2	check their figures going from table 2 to
3	table 4 because if they're correct then I'm
4	missing the concept somewhere.
5	MR. MORRIS: The spreadsheet has -
6	I can see it although I cannot manipulate it
7	to move around in it. What I can see is that
8	there's a set of columns that have the maximum
9	- the concentration by facility and then over
10	to the right of it it's like find the maximum
11	of these three posted in that column. So that
12	was the idea, Ron.
13	DR. BUCHANAN: Okay. And then
14	appendix, on page 38, just as an overview
15	there you're essentially releasing 34 curies
16	of activity per year into a certain size room
17	and it's stagnant in there. I mean, you don't
18	have an air exchange or anything like that,
19	you're just filling that room with that much
20	material and then doing a breathing rate and
21	then calculating the working levels per year,

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

201

1 is that correct?

2 MR. MORRIS: Those are - those are 3 the variables that in the were used 4 spreadsheet. They were just appears to be 5 copied and pasted into that appendix. And the 38 curies per year or 34 curies per year, that 6 7 was the value out of Meshkoff's paper, that was what went up the stack, part of what we 8 9 transported to a receiver location. So it 10 looks to me like this appendix came right out of the spreadsheet and you'll see how it's 11 used when you see it in the spreadsheet. 12

13 DR. BUCHANAN: Okay. Well, like I 14 we've only had this for a couple of say, We haven't had a thorough evaluation 15 weeks. 16 of it yet. I had some questions before I got dug deeper into it. I'll take a look at the 17 18 spreadsheet and also have someone that's really familiar with radon look at this and 19 20 probably write a short summary of our findings on it. 21

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

202

1	MEMBER LEMEN: Do you think you
2	can have it ready by our next meeting?
3	DR. BUCHANAN: By our next Weldon
4	Spring meeting, yes.
5	CHAIRMAN GIBSON: That was the
6	last issue that you guys had prepared?
7	MR. ROLFES: Correct, that's
8	correct. That summarizes the six responses
9	we prepared.
10	CHAIRMAN GIBSON: Okay.
11	DR. BUCHANAN: Excuse me, but you
12	did issue number 1 is the data. Issue 1, SEC
13	issue A and C is the validity of the data
14	that's used for dose reconstruction. That's
15	number 2, let me see, I don't know which one
16	it is on your list there. It's NIOSH's
17	response to issue number 1 identified in the
18	Work Group.
19	MR. ROLFES: All right. Let me
20	see.
21	DR. BUCHANAN: Verification of

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

203

accuracy and adequacy of the data, issue 1 A
 and C.

3 Okay that's on MR. ROLFES: the 4 back page. Let me make sure I've got the same thing. 5 Okay, yes, thank you Dave. Okay. 6 I didn't notice. Good catch, thank you. Yes. 7 We had an additional response, NIOSH response to issue number 1 identified in the Weldon 8 Spring Plant Working Group meeting. 9 Thanks, 10 Ron. It says, "During a meeting of the Weldon 11 Spring Plant Work Group NIOSH was requested to respond to a question regarding the origin of 12 the exposure record that NIOSH receives for 13 14 the Weldon Spring Plant workers and what information is available 15 to verify the 16 pedigree of that information." I'll just qo 17 ahead and read it, it's two paragraphs here. "Considerable analysis of the Weldon Spring 18 19 Plant bioassay data has been performed 20 comparing available data to the original data. The comparison of hard copy data to the CER 21

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

204

1 database performed during the SEC petition 2 evaluation intended not to provide was 3 evidence relative to records used by the dose dose 4 reconstructor. The reconstructor is 5 provided with all available records and uses 6 the hard original data for dose сору 7 reconstruction purposes whenever available. Weldon Spring did not produce an electronic 8 9 dosimetry database before the facility 10 operations shut down and DOE has not developed 11 а database for Weldon Spring dosimetry The dose reconstructors do not have 12 records. 13 direct access to the CER database. The 14 primary hard copy records from the site are original records that don't 15 the require 16 validity - excuse me, validation of V&V and 17 quality assurance. The CEDR and CER databases 18 are not primary records but were derived from primary records. The CER bioassay data was 19 20 computerized by 1978. Around that time Dr. Ellis reviewed the Destrehan and Weldon Spring 21

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

205

files and removed duplicate entries and took 1 care to verify outlier results against the 2 3 hard copy records. Additionally, Dr. Ellis sample comparison of the electronic 4 did a 5 files against the hard copy primary files. 6 The external dosimetry electronic file was 7 reviewed and the accuracy of that file did not satisfy Dr. Ellis. CER rebuilt the electronic 8 file from scratch from the primary hard copy 9 medical records." 10

11 DR. BUCHANAN: Okay, the reason 12 this came up was that they were, I guess part 13 of the process, the protocol is to verify the 14 of the data used for the dose accuracy reconstructor and the completeness of it. And 15 16 so we had been debating where this information 17 was because CER came up, database came up and 18 that sort of thing. And so we wanted to know, 19 you know, what was the dose reconstructor 20 actually using. So that's what was the question we asked I think at the last meeting. 21

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

(202) 234-4433 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

206

1	And so it looks like, and I've looked at some
2	of these dose reconstructions, and I did find
3	that the photocopy of the original handwritten
4	record or typed record is what the dose
5	reconstructor receives. So he's not using
6	some CER database or something to do dose
7	reconstruction. And so that's good.

does 8 Now that bring the up question of accuracy. 9 That's as far as that 10 half of the question. The other half is And so I think that we're 11 completeness, okay. supposed to due diligence to make sure that 12 13 the records that they received, bio and 14 external, are complete as possible. You know, are there large gaps or whatever. 15 And so 16 that's where issue number 1 A and C for both internal and external respectively set at this 17 looked like 18 point. Ιt the accuracy is However, the completeness has not 19 satisfied. 20 been addressed, but that can be - or whatever. Has there been any efforts made to show that, 21

NEAL R. GROSS

(202) 234-4433

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

207

1	you know, there's not large gaps, there's not
2	- no files missing. And of course that's a
3	subjective opinion but that's something that
4	the worker needs to address.
5	CHAIRMAN GIBSON: So do you have
6	enough information to go back and see if the
7	data is complete or do you need more
8	information from DCAS to verify your - or to
9	do the review? Or have you, your question is
10	you don't think there is adequate data.
11	DR. BUCHANAN: No, we don't have a
12	- we don't have an opinion one way or the
13	other at this time. We just, all we're saying
14	is that it's chartered that is supposed to be
15	done and it has not been done.
16	MR. FITZGERALD: Well, I think the
17	Board has its own procedures to look at
18	adequacy of the data and traditionally SC&A
19	has taken a look at that on behalf of the
20	Board. And on completeness, just looking at
21	precedent, what we've done in the past is

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

208

1	we've sampled. You know, you really can't
2	look at every single data point obviously.
3	You sample and see if there's obvious gaps in
4	terms of years or in terms of operations. You
5	know, whether it's clear certain operations
6	didn't have any data or it's clear you're
7	missing, you know, months without any obvious
8	explanation. You do a relatively small sample
9	and that comes out pretty much, you know,
10	okay, you typically stop there. If you do a
11	small sample but it comes up with some
12	discrepancies then you might take a larger
13	sample, if the Work Group wishes, and that's
14	worked in the past. That tends to be
15	effective given the circumstances. So that's
16	how we would do completeness. I think what
17	NIOSH has done in terms of looking at accuracy
18	is fine. But you know, again, I think the
19	completeness thing is a sampling exercise.
20	CHAIRMAN GIBSON: So we still need
0.1	to do that

to do that.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

209

1	MR. FITZGERALD: Yes and you know,
2	I think we can do that. I mean, without
3	splitting too many hairs, we can actually do
4	some small degree of sampling. I think we can
5	propose to the Work Group what a sample size
6	would look like and just do it and if it comes
7	up without any aberrations, say, or obvious
8	discrepancies by year or by you know scope of
9	operations then that would be it and we
10	wouldn't go any further.
11	CHAIRMAN GIBSON: Okay.
12	MR. FITZGERALD: I mean, so I
13	think what we would propose to the Work Group
14	is here's our sampling plan, a modest one, and
15	we would conduct that once we get your
16	approval and provide the results back to the
17	Work Group before the next meeting. And that
18	would be kind of it.
19	MR. KATZ: So if you want to send
20	a plan for that to the Work Group Members.
21	MR. FITZGERALD: Yes.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

210

1	MR. KATZ: You guys can email me,
2	say if you have any issues with it, and then I
3	can task this accordingly. That way we can
4	get it done without having another Work Group
5	meeting.
6	MR. FITZGERALD: Well, I think
7	again the dimension would be scope by virtue
8	of the operations and scope by virtue of the
9	years. Seems to be obvious gaps.
10	CHAIRMAN GIBSON: Okay.
11	DR. BUCHANAN: Do I send the
12	initial plan to you or?
13	MR. KATZ: Well, send it to the
14	Work Group Members and copy me too please.
15	DR. BUCHANAN: Okay.
16	MR. KATZ: And you might as well
17	copy everyone in case they have any comments
18	on the sampling plan as well.
19	MEMBER LEMEN: Would you send it
20	to both our email addresses, not just our CDC
21	address?

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

211

1	MR. KATZ: That's fine. If you
2	send it to me, if you don't have that I can
3	forward it on.
4	DR. BUCHANAN: Okay.
5	MR. FITZGERALD: But given the
6	size of this site, we did this for Class at
7	some of the bigger sites, this is definitely
8	going to be contained and modest but we'll see
9	if there's any indication first before we
10	propose anything further.
11	MR. KATZ: So officially - I mean
12	the Work Group doesn't meet when it's not
13	needed, so you can just individually tell me
14	if you have any issues. If you were to have
15	issues we can have a Work Group meeting to
16	iron them out.
17	CHAIRMAN GIBSON: Okay. So at
18	this point next point on the agenda, is there
19	any discussion of SEC issues either from DCAS
20	or SC&A? Or have we?
21	DR. BUCHANAN: There's one more.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

212

1	It	goes	along	-
---	----	------	-------	---

2	CHAIRMAN GIBSON: Oh, I'm sorry.
3	DR. BUCHANAN: This is Ron. On
4	l(d) is coworker model - and I guess at this
5	point we would like clarification on what
6	coworker model NIOSH plans to use both
7	internally and externally. Because there's
8	been different statements for the TBD, the ER
9	and then this - the environmental part. We'd
10	like clarification on what coworker model is
11	proposed.
12	MR. ROLFES: For external and
12 13	MR. ROLFES: For external and internal, is that what you said? For both?
13	internal, is that what you said? For both?
13 14	internal, is that what you said? For both? DR. BUCHANAN: Yes, for both.
13 14 15 16	internal, is that what you said? For both? DR. BUCHANAN: Yes, for both. MR. ROLFES: As of right now I
13 14 15 16	<pre>internal, is that what you said? For both? DR. BUCHANAN: Yes, for both. MR. ROLFES: As of right now I don't believe we've identified a need for one</pre>
13 14 15 16 17	<pre>internal, is that what you said? For both? DR. BUCHANAN: Yes, for both. MR. ROLFES: As of right now I don't believe we've identified a need for one because it appears that the people who needed to be monitored have been monitored. If we</pre>
13 14 15 16 17 18	<pre>internal, is that what you said? For both? DR. BUCHANAN: Yes, for both. MR. ROLFES: As of right now I don't believe we've identified a need for one because it appears that the people who needed to be monitored have been monitored. If we</pre>

NEAL R. GROSS

(202) 234-4433

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

213

1	would consider it at that time I believe.
2	DR. BUCHANAN: Well, because - the
3	reason I bring it up is in the - because the
4	environmental work here paper that you just
5	gave out said that - well, you just told Mike
6	that the person that was onsite but not in
7	operations, the reason he was doing the
8	modeling and stuff was to assign dose to that
9	person. And so I guess that indicated that
10	there would be some coworker model data used.
11	MR. ROLFES: Well, the
12	environmental ambient intakes would be for
13	someone who didn't work necessarily in the
14	production area and we have indication that
15	the people that were working in the production
16	area were monitored appropriately. There may
17	have been some people that worked next to the
18	production area and really, it's not really
19	appropriate for us to assume that they were
20	exposed at the same level as the production
21	workers onsite. We're talking, you know, more

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

214

1	administrative type personnel that aren't
2	working inside of the production areas.
3	MR. MORRIS: Mark, this is Robert
4	Morris.
5	MR. ROLFES: Yes.
6	MR. MORRIS: I'd clarify that.
7	You know, nobody was monitored for radon that
8	I'm aware of so -
9	MR. ROLFES: Right.
10	MR. MORRIS: So to the extent that
11	that's true we will have to use environmental
12	doses for radon for anybody. Whether the dose
13	is from inside of the building where it's
14	higher or outside the building where it's not,
15	where it's lower concentrations, the
16	dispersion modeling is the only difference
17	there. So that is the exception as I
18	understand it.
19	MR. KATZ: That doesn't sound like
20	a - that's not a coworker model per se.
21	MR. MORRIS: No, I don't think of

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

215

1	that as a coworker model, Ted.
2	MR. FITZGERALD: I guess - this is
3	Joe. Just as an extension of what we just
4	talked about on the completeness review, what
5	- I guess is the interest on the basis for I
6	guess the conclusion that everybody who should
7	be monitored was monitored, the data is
8	complete. Because that's kind of what we're
9	sampling so I'm curious as to how you got
10	there because that would help us understand.
11	MR. ROLFES: Sure. For example,
12	there was a subset of employees, the female
13	population in the earlier years was not
14	monitored because they weren't working within
15	the production area.
16	MR. FITZGERALD: Right.
17	MR. ROLFES: So there's approaches
18	that we can use certainly if we have
19	indications that a female was you know
20	routinely entering a production area or an
21	unmonitored person. And that has to be taken,

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

216

you know, as a case by case basis. If there's 1 2 information that supports that did occur, that 3 an individual was not monitored and was in the production area then that would be, you know, 4 5 we'd I guess have to address that when it was Based on my knowledge on 6 identified to us. 7 the review of dose reconstructions that have been done there have not been any incidents 8 9 where we've seen someone that should have been 10 monitored and was not monitored. 11 MR. FITZGERALD: Okay. Well, I just want to draw the distinction. 12 You're 13 saying it was an empirical judgment because

14 you're basically saying that you haven't seen 15 it yet so therefore it's not likely.

16 MR. ROLFES: There's always
17 exceptions and -

18 MR. FITZGERALD: Well, I'm iust 19 saying that in terms of coworker, a coworker 20 decision I think what Ι think we've we _ 21 established the completeness qoinq-in as а

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

217

1 proposition as to whether a coworker model 2 would be warranted. I'm just saying that this 3 is - so we're kind of approaching it from that I think what you're saying is 4 perspective. 5 that empirically you've done enouqh dose 6 reconstructions, you haven't seen any gaps so 7 at this point in time you feel comfortable. Ι just want to make sure that's clear to the 8 9 Work Group. And we're going to validate that, 10 maybe doing a little more upstream and going 11 through that analysis. You're looking at things like I guess, you know, 12 maintenance 13 workers, kind of those category workers where 14 you tend to maybe find issues with gaps. But okay, that helps. I guess it doesn't 15 So 16 change anything we're planning on doing as far 17 as completeness, but - one - the useful thing of course would be seeing whether or not we 18 19 think there are certain gaps in certain 20 categories or years and then marrying that up with the dose reconstruction experience to see 21

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

218

1	if it in fact uses - actually have done it.
2	So that would kind of answer that issue. Does
3	that?
4	DR. BUCHANAN: Yes, okay.
5	CHAIRMAN GIBSON: Okay. Ron, do
б	we have any SEC issues that we need to
7	discuss, that we're prepared to discuss? Or
8	are there some we're not prepared to discuss
9	but we need to keep on the agenda?
10	DR. BUCHANAN: This covered all of
11	my issues - oh no, no, let's see. Let me - he
12	didn't - yes. The issues that were covered
13	today did not include site with uranium to -
14	let's see. We did discuss that to a certain
15	extent, okay.
16	MR. ROLFES: But we do have
17	another response that is in the works that
18	we'll send out as soon as it's available.
19	DR. BUCHANAN: Was the geometry
20	and extremity, issue 9, was not addressed. It
21	was on the chart last time.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

219

1	MR. KATZ: For RU? Didn't we have
2	a time frame for that, we already talked about
3	that?
4	MR. ROLFES: Yes, the report's
5	actually sitting on my desk.
6	MR. KATZ: Oh, that's right.
7	That's the one. Okay. So that's fairly soon
8	that that'll be presumably delivered to the
9	Work Group.
10	MEMBER LEMEN: What, the geometry?
11	MR. KATZ: The RU. RU.
12	MEMBER LEMEN: Okay.
13	MR. ROLFES: Now, as far as
14	geometry I think we have an approach
15	documented in our - I'm trying to recall what
16	document it is. But there were some comments
17	I think that we had received previously and I
18	think we looked at those and I'm probably
19	going to ask for help on the phone. The
20	geometry issues I think SC&A had identified
21	that they had reviewed the NIOSH approach to

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

220

1	interpret film badge data for Mallinckrodt
2	Chemical worker employee exposures and we have
3	a specific TIB that addresses those geometry
4	correction factors. I think SC&A had reviewed
5	that and had some comments on them and I
6	believe we're in the process or have resolved
7	those comments with SC&A. And so I don't know
8	what else there might be that we need to
9	respond to there, but we can - we can -
10	Monica, is there anything else in there that -
11	I know we had discussed this a little bit. We
12	had - let's see.
13	MS. HARRISON-MAPLES: Are you
14	asking me in terms of other issues that need
15	to be?
16	MR. ROLFES: Yes. I remember
17	there was some uncertainty we would - we said
18	that we would look at some of SC&A's comments
19	on the external geometrical correction factors
20	that were applied for Mallinckrodt workers.
21	And I want to say that we had looked at that

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

221

1	but didn't see anything applicable.
2	MS. HARRISON-MAPLES: We did. I
3	think that is in - that was in one of the
4	responses that we -
5	MR. ROLFES: Yes. Okay, I do have
б	it here. This was part of the NIOSH response
7	to SC&A's Weldon Spring site SEC petition
8	finding 2, a lack of personnel contamination
9	egress monitoring. And on the last page of
10	that document the last paragraph states that
11	NIOSH has reviewed both the Mallinckrodt
12	Chemical Works and Bethlehem Steel Site
13	Profile review documents and found nothing
14	that would suggest either of those sites did
15	anything different than Weldon Spring Plant to
16	address skin contamination nor was there any
17	greater in-depth review or treatment of skin
18	doses as was suggested previously. So maybe
19	we need to address the geometrical correction
20	factor portion of that, but from what I recall
21	I think we've got an approved OTIB and I don't

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

222

1	know the number off the top of my head as to
2	what that - it's - I think it's like special
3	dose reconstruction considerations for
4	Mallinckrodt Chemical workers. Does that ring
5	a bell to anyone?
б	MR. M. SMITH: Yes, it's OCAS TIB-
7	10. I'm sorry, OCAS TIB-13.
8	MR. ROLFES: OCAS TIB-13. Okay.
9	That must have been Matt.
10	MR. M. SMITH: Yes, it's Matt.
11	MR. ROLFES: Thank you, Matt. So
12	we need to take a look at that.
13	DR. BUCHANAN: So that's for
14	Mallinckrodt Chemical workers, right? TIB-13?
15	MR. ROLFES: That's correct, and I
16	think that's what SC&A had asked us to look
17	at. So we went back and looked at that and I
18	don't believe we saw anything. We should have
19	specified that in our response here. We only
20	addressed skin contamination. But let me give
21	you an update on that as well. When I get

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

223

back into the office I'll send out an update
about the geometrical correction factor
issues, if there's anything that's different
between Mallinckrodt and Weldon Spring.
DR. BUCHANAN: Okay.
MEMBER LEMEN: Anything else?
DR. BUCHANAN: Yes, that's us.
MR. KATZ: So I think we still
need to clarify then whether the Work Group
has anything more to do with respect to the
'67 discussion and also the - let's start with
that I guess. I think there was one other.
The path forward was a little bit murky, if
there is a path forward.
MEMBER LEMEN: The '60s.
MR. KATZ: '67, what we discussed
was that DCAS, Mark and company discussed the
various - and Monica, the various documents
there are which are sort of suggestive of what
did or didn't happen in '67. And he also
discussed at least one of the cases where it

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

(202) 234-4433

1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701 www

224

1	was contended someone did work and Monica
2	provided I guess the DCAS interpretation that
3	that person's work activities fit into a
4	Department of Army activity that was over -
5	spanned from '67 or '68 to '69. That was the
6	most sense they could make of that, that
7	discussion from that - I guess from a - was
8	that from an OCAS interview? A normal dose
9	reconstruction interview?
10	MR. ROLFES: I think that was
11	actually from an affidavit that was previously
12	provided. SC&A had identified it and we
13	looked at that. I don't recall if we re-
14	interviewed that same person or not.
15	MR. KATZ: Okay, so it wasn't a
16	dose reconstruction interview, it was an SC&A.
17	MR. ROLFES: I believe so.
18	DR. BUCHANAN: Personal interview
19	but there was no date.
20	MR. KATZ: Personal interview,
21	yes.

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

225

1	DR. BUCHANAN: There was no date.
2	The worker did not give an exact date -
3	MR. KATZ: Right.
4	DR. BUCHANAN: - of when it took
5	place.
6	MR. KATZ: Right.
7	DR. BUCHANAN: It was between '67
8	and '69.
9	MR. KATZ: Right. So you have an
10	interpretation based on DCAS documents of what
11	- where that work experience might fit and
12	DCAS's interpretation of what's gone on in
13	that period '67 and after.
14	CHAIRMAN GIBSON: So at this point
15	the information about '67 is of no consequence
16	to us unless there's a future claimant that
17	has an affidavit or such that he did something
18	in '67 that we need to -
19	MR. KATZ: Yes.
20	CHAIRMAN GIBSON: Okay.
21	MR. KATZ: I think that's right.

(202) 234-4433

226

1	I think if someone comes forward with concrete
2	recollection or information that there were
3	activities that haven't been captured so far
4	in what people understand, I think that
5	situation just rests as it is until -
6	CHAIRMAN GIBSON: I mean, this
7	currently doesn't apply to any claimants.
8	MR. KATZ: Right.
9	CHAIRMAN GIBSON: If it comes to
10	the point that it does.
11	MR. KATZ: So it's - I think you'd
12	call this closed for the time being. Of
13	course it could be reopened if there were a
14	basis for reopening it.
15	MEMBER LEMEN: Anything else, Ted?
16	MR. KATZ: Well, let me just see.
17	I think there was - oh, the other - well, the
18	other item that we haven't really clearly
19	resolved was the discussion about the skin
20	contamination egress monitoring that was left.
21	At least it was unclear to me whether - if

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

227

1	there is a path forward on that.
2	DR. BUCHANAN: Well, SC&A doesn't
3	have any more to offer. I mean, we just - we
4	brought it up and we looked at the response
5	and it appears to be, you know, similar to the
6	other uranium working plants. But you know,
7	we really don't have any more to add.
8	MEMBER LEMEN: So that can be
9	closed?
10	DR. BUCHANAN: We have no new
11	evidence or anything.
12	MR. ROLFES: Just keep in mind
13	also that is something that we do look at in
14	an individual's telephone interview and in
15	their DOL initial case files. If an
16	individual does mention contamination and it's
17	something that could make a difference in the
18	dose reconstruction outcome then it's
19	certainly considered. There have been cases
20	where we've done skin calculations and such to
21	account for any skin contamination issues.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

228

1	You know, a lot of it is important as to where
2	you know skin cancer would be. For an
3	external contamination issue it would be a
4	skin cancer organ - excuse me, skin cancer
5	would be for the skin would be the most likely
6	affected organ from surface contamination that
7	remained there for, you know, a long time.
8	We'd have to take a look at the specifics of
9	you know where that skin cancer was located
10	and such. If it was under clothing then it's
11	very unlikely that surface contamination on
12	the clothing would have contributed a
13	significant amount of dose that was not
13 14	significant amount of dose that was not recorded to that particular skin cancer
14	recorded to that particular skin cancer
14 15	recorded to that particular skin cancer location. You know, if - there's more
14 15 16	recorded to that particular skin cancer location. You know, if - there's more specific case details that are needed to make an assessment of the dose and that is
14 15 16 17	recorded to that particular skin cancer location. You know, if - there's more specific case details that are needed to make an assessment of the dose and that is something that has been done in dose

21 this is where this to - this issue seems

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W. (202) 234-4433 WASHINGTON, D.C. 20005-3701

229

end back with 1 alwavs seems to this same 2 discussion. 3 We've heard it MR. FITZGERALD: 4 many times. 5 MR. KATZ: Yes. CHAIRMAN GIBSON: We can qo ahead 6 7 and close it then. If it comes up related to a future claim then we can reopen it. 8 9 MR. KATZ: Okay. So do we want to 10 - do we want to run through the action items 11 here or do people want to just deliver that by 12 paper, Ron and Mark? Okay. I have notes if 13 people, if either Ron or Mark wonders, I've 14 taken notes. I think I've captured it. CHAIRMAN GIBSON: The only thing 15 16 I'd ask is when they're noted by paper, you 17 know, SC&A will put theirs out and DCAS will. Let's make sure they mesh up so that when we 18 19 set an agenda for another meeting -20 MR. KATZ: That should be one 21 So who wants to take the - do you document.

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

(202) 234-4433

1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

230

want to take the first stab at putting out an
action item list that covers both?
DR. BUCHANAN: Okay. Yes, I can
do that.
MR. KATZ: And then Mark can
confirm or amend.
MEMBER LEMEN: Would you put that
on the OCAS site or how will you give it to
us?
MR. KATZ: So he'll distribute it
to the full Work Group and Mark can -
MEMBER LEMEN: Are you going to
send it to our particular address and not the
CDC address?
DR. BUCHANAN: Okay.
MR. KATZ: And then Mike, do you
want to chat with - about the Work Group
update for the Board? Do you need to chat
about that? Do you want help from Ron or
anyone or DCAS in preparing?

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

231

1	mean I could use any help because you know,
2	it's - it don't seem we're making progress I'd
3	like for it.
4	MR. KATZ: Well, I think you
5	actually - I mean, you have - you've gotten -
6	I mean, you've put to bed a lot of issues. I
7	mean, you're not finished but -
8	MEMBER LEMEN: If we can get the
9	list and we can get it before the Board
10	meeting that would be the purpose of what you
11	say to the Board.
12	MR. KATZ: Well, after the action
13	item is put - I mean, it'd be nice given that
14	you have - you're in St. Louis, it'd be nice
15	to give them sort of an overview of what the
16	issues were originally and here is where we
17	are. It'd be nice, a summary.
18	CHAIRMAN GIBSON: Yes. If DCAS
19	and SC&A could put out that summary or send it
20	to me just so I know that they both agree on
21	what's out there and what's open, what's

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

232

1	closed so that there won't be no discrepancy.
2	MR. KATZ: So Ron, would you be
3	willing to maybe do this in a PowerPoint
4	fashion to make it easy for Mike? Is that all
5	right with you, Mike, in PowerPoint?
6	CHAIRMAN GIBSON: Sure.
7	MR. KATZ: Just a sort of
8	simplified overview of what the issues have
9	been and where they stand.
10	DR. BUCHANAN: SEC or Site Profile
11	and SEC?
12	MR. KATZ: I think you can focus
13	on the SEC, but you can - in the tail end
14	there it wouldn't be a bad thing to list what
15	any of the more major TBD-type issues and
16	where those stand as well. He has 15 minutes
17	so it's not - it's not going to be interactive
18	with petitioners because it's just a report,
19	it's not an update. But it'll just be - it'll
20	be just before we go to public session and I
21	think it'd be nice for the people there from

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

(202) 234-4433

233

1	Weldon Spring to sort of get - most of them
2	won't have been listening to any of these
3	calls. It would be nice for them to just get
4	a sense of what kind of progress has been made
5	on their petition, in particular on the
6	petition, but on the site in general. So, but
7	I think you can do a very nice job of sort of
8	describing the site itself and what activities
9	went on there and I think that's sort of a
10	nice place to begin for Mike because not
11	everybody there will even understand the site
12	that well even if they've had a surviving
13	member who worked there. It'd be good for
14	them to get a little bit of that overview.
15	DR. BUCHANAN: Okay.
16	MR. KATZ: Thank you. And if you
17	could just - if you could distribute that
18	maybe - I know there's not a lot of time now,
19	but if you could get that to the Work Group
20	just maybe a week in advance of the Board
21	meeting?

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

234

1	MEMBER LEMEN: That's next week.
2	MR. KATZ: Yes. I mean it's not a
3	lot of time, but it's a fairly simple brief
4	presentation. Then everybody can just have a
5	glance at it and if anyone has anything to
6	throw into the.
7	DR. BUCHANAN: I'll try to get it
8	out at the end of this week. That way
9	everybody will have a chance to look at it.
10	MR. KATZ: That's great. If you
11	could do that it would be great.
12	MS. LIN: It needs to be PA
13	reviewed.
14	DR. BUCHANAN: Okay. Yes, I can
15	give it to the Board Members to look at before
16	I finalized anything.
17	MR. KATZ: Yes, and that's easy
18	because they won't have anything except that.
19	And it has to run through.
20	DR. BUCHANAN: And Nancy has to
21	look at it, is that right?

235

1	MS. LIN: Nancy Johnson will
2	submit it to the OGC.
3	DR. BUCHANAN: Okay. I'll send it
4	to her. When we finalize it I'll send it to
5	Nancy and then she'll take care of it from
б	there. Okay.
7	MR. FITZGERALD: Don't include any
8	interesting pictures.
9	DR. BUCHANAN: Don't include any?
10	MR. KATZ: Not interesting ones.
11	Not interesting ones, but a picture of the
12	site would be fine.
13	MR. FITZGERALD: Yes, a picture of
14	the site.
15	DR. BUCHANAN: Well, you've got 15
16	minutes, you've got 15 slides. That's the
17	rule of thumb, right?
18	CHAIRMAN GIBSON: That's - I
19	believe so. You do the St. Louis meeting and
20	after that we'll try to set a date for another
21	Work Group meeting.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

236

1	MR. KATZ: It sounds like it can
2	happen relatively soon from my sense of where
3	everything stands. Everything seems right on
4	the verge of being delivered or if there are
5	follow-up items that don't sound like they'd
6	take very long. It seems like we might be
7	able to meet in June or?
8	CHAIRMAN GIBSON: We can schedule
9	it while we're in St. Louis -
10	MR. KATZ: Sure.
11	CHAIRMAN GIBSON: Okay. Other
12	than that there's nothing else.
13	MR. KATZ: We're adjourned.
14	CHAIRMAN GIBSON: We're adjourned.
15	MR. KATZ: Thank you everybody.
16	Thank you everybody on the line as well.
17	MS. M. JOHNSON: Excuse me?
18	MR. KATZ: Yes?
19	MS. M. JOHNSON: Excuse me?
20	MR. KATZ: Yes? Hello?
21	MS. M. JOHNSON: This is Mary

(202) 234-4433

237

1	Johnson. Could I please make a comment?
2	MR. KATZ: Yes. Yes, Mary, what's
3	your last name? Sorry?
4	MS. M. JOHNSON: Johnson.
5	MR. KATZ: Johnson. Yes, go
6	ahead, Mary.
7	MS. M. JOHNSON: First of all, I
8	would like to tell you that I have the utmost
9	respect and admiration for the knowledge and
10	expertise you bring to this program. However,
11	I do have some concerns. I have listened to
12	all the Work Group meetings. I have read all
13	the documents that have been sent out, all the
14	studies, and I was hoping that with this Work
15	Group meeting today I would have some sort of
16	feeling of where we stand at Weldon Spring
17	with our SEC petition. After listening I am
18	more concerned than ever. I saw some
19	questions answered but I thought I heard as
20	many questions asked as answered which means
21	more time.

NEAL R. GROSS

238

1	I am overwhelmed with the
2	knowledge that you all have. I understand
3	probably very limited amount of it, but enough
4	to know or get the gist of where we stand. I
5	would like if you all can to please step back
6	for just one moment and be a claimant. This
7	whole process is overwhelming. The longer it
8	goes on, the more overwhelming it becomes. I
9	don't want to use the word "giddy" loosely but
10	we're almost to the point where we think wait
11	a minute, you know, I'm impressed with all
12	this knowledge and all this study, but we're
13	the claimants. Don't forget us out here.
14	We're waiting, waiting and waiting for an
15	answer and it is beyond frustrating.
16	And I urge you not to come to St.
17	Louis with the idea that we're just going to
18	hear a synopsis of what has gone on so far and
19	more time is needed. We urgently need an
20	answer. Too many of us are dying. We're just
21	- I can't tell you how frustrated we are. And

NEAL R. GROSS

(202) 234-4433

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

239

1	we need an answer, whether it's yes, no or
2	indefinite, we need an answer. And so I urge
3	all of you to please bring that to St. Louis
4	when you come. There will be a multitude of
5	us there and we want an answer. And that's
6	all I have to say. Thank you for your time
7	and for listening to me.
8	MR. KATZ: Thank you, Mary. Okay,
9	we are adjourned.
10	(Whereupon, the above-entitled
11	matter went off the record at 3:26 p.m.)
12	
13	
14	
15	